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Despite long-term research efforts to identify a cohesive explanation of racial disparities in 
cancer outcomes, evidence remains mixed. Disparities persist in randomized clinical trials, 
suggesting that inherited factors contribute to differential outcomes. Hemoglobin variants 
represent a heretofore unstudied inherited prognostic factor, the most prevalent of which is sickle 
cell trait (SCT). SCT is disproportionally prevalent in African American/Blacks (AA/Bs) (~8%) 
compared to non-Hispanic whites (NHWs) (<0.1%). Case report evidence suggests SCT interacts 
with the tumor microenvironment and rigors of cancer treatment, inducing adverse outcomes. 
We identified 162,357 older cancer patients (75,633 breast; 86,904 prostate) diagnosed 2007-
2013 using the SEER-Medicare linked database. AA/B and NHW patients were grouped by 
hemoglobinopathy status (AA/B+, AA/B-, NHW-) and three-way propensity score weighting 
was performed to evaluate treatment completion, occurrence of adverse events, and survival. A 
total of 371 AA/B+ patients were analyzed, compared to 17,303 AA/B- and 144,863 NHW-. At 
diagnosis, AA/B+ were more likely than AA/B- and NHW- to have multiple comorbidities 
including cerebrovascular disease, diabetes, and chronic renal failure. After propensity score 
weighting, no significant association was observed in treatment completion status between 
AA/B+ and AA/B-. Among treated patients, however, AA/B+ status was associated with 
increased risk of experiencing one or more adverse event compared to both AA/B- (HR: 1.15, 
95% CI: 1.07 – 1.24) and NHW- (HR: 1.18, 95% CI: 1.10 – 1.26). While hazards models failed 
to reveal significant differences across study groups, the magnitude of the associations with
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mortality in relation to either treatment completion or adverse events varied by 
hemoglobinopathy status.  Among AA/B+ who completed treatment, those who experienced one 
or more adverse events had more than five times the mortality risk compared to those with no 
adverse events (HR: 5.56, 95% CI: 4.70 – 6.58) whereas the estimated mortality risk among 
AA/B- and NHW- patients were approximately three-fold. Among patients who failed to 
complete treatment, however, the adverse event-mortality relationship was similar across groups. 
This study, to our knowledge, provides the first analytical evidence of SCT and other 
hemoglobinopathies as prognostic biomarkers in cancer, acting as important effect modifiers of 
the association between treatment completion, adverse events, and mortality.  
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1.0 Introduction 
1.1 Background 
1.1.1 Racial disparities in cancer outcomes 
Cancer is the leading cause of death in the United States (US) among men and women 
ages 40-79 and the second-leading cause of death in the US overall, accounting for 23% of all 
deaths and over 550,000 deaths annually.1 Compared to non-Hispanic Whites (NHW), the 
African American/Black (AA/B) population experiences 22.3% and 12.6% higher all-site cancer 
mortality rates for men and women, respectively; AA/B women are 40% more likely to die from 
breast cancer than NHW women in the US, and AA/B men are more than twice as likely to die 
from prostate cancer than NHW men.1 Despite the steady decline in cancer mortality rates since 
the 1990s in all groups, largely attributed to the introduction of improved cancer therapies and 
screening techniques2, racial disparities persist.3 The largest racial disparities in cancer-specific 
mortality have persisted for over three decades within breast and prostate cancer, the two most 
prevalent cancers among AA/B women and men, respectively.3  Further, the survival gap has 
increased between AA/B and NHW breast cancer patients1,3, hence, novel questions are 
warranted.4 
Established and putative explanatory factors of racial disparities in cancer outcomes 
reflect a complex interplay across three major domains5: 1) macroenvironment level; 2) 
individual environment level; and, 3) biologic levels such as cellular biomarkers and inherited 
genetic variants.5 Applying this multilevel approach to disparities research for cancer outcomes 
has highlighted interactions among and between macroenvironment factors such as geography 
and latent discriminatory policies and practices that reduce access to and completion of high 
quality cancer care with local/individual factors such as socioeconomic deprivation, 
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comorbidities, and lower rates of healthcare utilization.6-8 Despite an extensive body of research 
documenting these contributions to outcome disparities, a composite analysis of randomized 
clinical trials (RCTs) from the Southwest Oncology Group (SWOG) reported that racial 
disparities in breast and prostate cancer survival remained after controlling for clinical 
presentation (e.g., stage, histology, and tumor characteristics) among patients with similar 
eligibility requirements who received uniform therapy.9 These findings suggest that unmeasured 
factors, such as genetic status, may be associated with persistent outcome disparities.10 
Specifically, our current investigation focuses on the prognostic role of a prevalent 
inherited genotype in the AA/B population, sickle cell trait (SCT), which to date has not been the 
object of a systematic investigation in cancer outcomes. This topic was prompted by a recent 
report of multiple cases with SCT and sickle cell disease (SCD) who experienced various 
adverse events during systemic chemotherapy or whose tumors exhibited increased hypoxia.11 
SCT is the most common genetic mutation of hemoglobin worldwide; in the US, the prevalence 
of SCT is comparatively high in the AA/B population at 8.0% compared to < 1.0% of NHWs.12 
Additional hemoglobinopathies are included in this investigation as described later.  
SWOG findings also could be explained by residual confounding due to differences in 
tumor clinicopathology. For example, in an analysis of 373,563 women diagnosed with invasive 
breast cancer from 2004 to 2011 in the Surveillance, Epidemiology, and End Results (SEER) 18 
registries database, AA/B women with small tumors (less than or equal to 2 cm) were more 
likely to present with lymph node metastases (24.1% vs. 18.4%, respectively, p < .001) and 
distant metastases (1.5% vs. 1.0%, respectively, p < .001) compared to NHW women.13 
Population-based gene expression profiling of intrinsic breast cancer subtypes has revealed a 
 3 
 
much higher prevalence of aggressive basal-likei tumors among premenopausal AA/B woman 
compared to postmenopausal AA/B and non-AA/B women of all ages, and a lower prevalence of 
less aggressive luminal Aii tumors.14 In spite of these differences, however, the incidence of more 
aggressive tumor subtypes has not accounted for worse breast-cancer specific survival in AA/B 
women compared to NHW women, particularly among women with stage I disease.13,14  
Further, evidence from an RCT examining long-term follow-up of adjuvant taxane therapy in 
approximately 5,000 (8% AA/B) women with stage II and III breast cancer suggested that even 
among patients with more favorable ER positive disease, AA/B women were at higher risk of 
recurrence and experienced worse overall survival after adjustment for obesity, disease stage, 
and treatment adherence.15 Since AA/B women diagnosed with breast cancer exhibit greater 
intratumor genetic heterogeneity compared to NHW women, it could be that overall genomic 
instability, epigenetic changes, or some other inherited influence(s) are contributing more 
aggressive and/or treatment resistant disease.16 Whether the presence of SCT or other inherited 
hemoglobinopathies play a role in tumor metastasis and treatment resistance is unknown. 
Studies of genetic variation in drug metabolizing genes across populations have reported 
reduced cancer survival17 in relation to certain genotypes, and can serve as a general model for 
studying the impact of SCT and other inherited hemoglobinopathies on clinical outcomes.18 
Adverse drug responses may materialize as lower tumor response rates and increased systemic 
toxicity, which can lead to non-standard dose adjustments, treatment discontinuation, and worse 
survival. For example, hematologic toxicity (i.e. leukopenia and anemia) from chemotherapeutic 
antimetabolites such as 5-fluorouracil (5-FU) is significantly more prevalent in AA/B patients 
                                                 
i Basal-like: estrogen receptor (ER) negative, progesterone receptor (PR) negative, human epidermal growth factor receptor-2 (HER2) negative, 
cytokeratin 5/6 positive, and/or HER1 positive. 
ii Luminal A: ER positive and/or PR positive, HER2 negative. 
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compared to NHWs, likely attributable to higher prevalence of dihydropyrimidine 
dehydrogenase (DPD)iii deficiency (8% in AA/B compared to 2.8% in NHW).18,19 DPD 
deficiency is thought to be the result of germline polymorphisms in a host of genes with greater 
population frequencies in AA/Bs compared to NHWs and other genetic ancestries. Other 
chemotherapeutic adverse drug responses that could be due to differences in genetic ancestry and 
are more likely among AA/B compared to NHW include cardiotoxicity from anthracyclines18,20, 
cisplatin-induced nephrotoxicity, and lower maximum tolerable dose.20,21 Predicted adverse 
events related to SCT and other hemoglobinopathies are discussed in detail in section 1.1.4, and 
the biologic plausibility is proposed in section 1.1.5. 
Despite the documented history of racial disparities in cancer outcomes in the US and 
evidence for distinct chemotherapy-related toxicities between AA/B and NHW cancer patients, 
there is no available research outside of a collection of case reports regarding the impact of 
inherited hemoglobinopathies on cancer related adverse drug response and outcomes.11 In a 
secondary analysis of the large SEER-Medicare claims database, we will evaluate if there is an 
association between sickling hemoglobinopathies and adverse events in cancer patients and if 
these events contribute to racial disparities in cancer survival. 
 
1.1.2 Epidemiology of hemoglobinopathies: Sickle cell trait and sickle cell anemia 
Sickling hemoglobinopathies are the result of mutations that occur in the beta globin 
gene, one component of the hemoglobin (Hb) protein.22 SCT (commonly abbreviated HbAS) is a 
monogenic inherited heterozygous single base pair substitution (p.Glu7Val, rs334) in the Beta 
globin (HBB) gene on chromosome 11. Red blood cells (RBCs) of SCT carriers generally 
                                                 
iii DPD is the rate-limiting enzyme of 5-FU catabolism18,19 
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contain 35-40% abnormal hemoglobin (HbS), but this proportion is not static either within or 
between individuals with SCT.22-24 SCT is prevalent in approximately 1 in 12 (8%) AA/B in the 
US and the incidence of SCT is 25 times higher in AA/B compared to NHW, and 10 times 
higher compared to Hispanics.12 Sickle cell anemia (SCA, commonly abbreviated HbSS) is the 
most common genetic disorder of SCD and occurs through homozygous inheritance of the 
p.Glu7Val mutation in HBB. SCD has an estimated prevalence of approximately 1 in 365 AA/B 
in the US, compared to approximately 1 in 16,000 Hispanics, and less than 0.1% in the NHW 
population.25 For individuals with SCD, conditions of either local or systemic deoxygenation can 
cause abnormal beta globin to polymerize hemoglobin within RBCs thus disturbing RBC shape 
and ease of circulation with a propensity to adhere to the endothelium.22  
 
1.1.3 Epidemiology of hemoglobinopathies: Thalassemia disorders 
Thalassemia disorders and associated variants in the US are characterized by mutations in 
either alpha or beta globin genes that result in reduced or absent production of hemoglobin. The 
prevalence of thalassemia in the US is increasing and is driven primarily by increased 
immigration from affected regions in Asia and Arab countries.26,27 Among newborns screened in 
California, the prevalence of the beta-thalassemia variant Hb H represents over 80% of 
thalassemic conditions.26 Similarly, Hb E (the second most common hemoglobin variant in the 
world after SCT28) is often co-inherited with Hb H and is most commonly prevalent among 
individuals from Cambodian and Thai/Laotian ancestry, respectively.29 Thalassemia disorders 
are prevalent around the world with estimated ranges from 5 to 40% across Western Africa, the 
Eastern Mediterranean, Middle East, and Southeast Asia.30 
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1.1.4 Clinical complications associated with hemoglobinopathies 
Clinical manifestations of SCD are a consequence of the accumulation of rigid sickled 
RBCs that adhere to the vascular endothelium and obstruct blood flow, triggering both hemolysis 
and vaso-occulsive “sickling crises” from tissue hypoxia, enhanced apoptosis, tissue necrosis, 
and organ damage.22 Complications of sickling crises include severe intermittent pain, 
susceptibility to infection, stroke, organ failure, and early death.31 Historically, SCT has been 
considered a benign condition that confers a protective effect against malaria, but recent 
evidence suggests that SCT may be related to numerous health conditions.32 In addition to 
exercise-related sudden death, some adverse health complications associated with SCT include 
renal medullary carcinoma, hematuria, renal papillary necrosis, hyposthenuria, splenic infarction, 
and exertional rhabdomyolysis.33,34 Known factors associated with rare but clinically significant 
adverse outcomes include hypoxemia, acidosis, and dehydration; most of which are often 
encountered during periods of intense exercise, under extreme heat, or at high altitudes.35 The 
proposed pathophysiological mechanisms through which individuals with SCT experience 
exertional injury and death include slight decrease in RBC deformability, increase of whole 
blood viscosity, oxidative stress, and systematic inflammation.36 It should be noted, however, 
that the magnitude of these responses is less than that observed among individuals with SCA.36 
Recent large observational cohort studies have revealed additional adverse associations 
with SCT. For example, a cross-sectional analysis across four dialysis centers in three North 
Carolina counties found that SCT was twice as common among AA/B with end-stage renal 
disease (ESRD) compared with the general AA/B population (15% vs. 7%, p<0.001).37 
Subsequently, Naik et al. (2014), in a pooled analysis of 15,000 AA/B from five population-
based cohorts found a positive association between SCT and chronic kidney disease (CKD) 
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within each cohort.38 Another prospective study of AA/B adults (mean age of SCT carriers: 53; 
SD: 6) found a positive association between SCT and stroke, with increased risk observed after 
controlling for demographics and traditional cerebrovascular risk factors.39 In a prospective 
cohort of AA/B followed from 1987 through 2011 in the Atherosclerosis Risk in Communities 
Study, the adjusted hazard ratios of venous thromboembolism and pulmonary embolism were 
1.50 (95% CI: 0.96 – 2.36) and 2.05 (95% CI: 1.12 – 3.76), respectively, for participants with 
SCT compared to those without SCT.40 The characterization of adverse events associated with 
SCT continues to evolve, with a focus on impact on morbidity as well as clinical mechanisms of 
disease. 
In contrast to sickling hemoglobinopathies, the range of different clinical phenotypes 
represented in thalassemia disorders is less heterogeneous; the most common complication of 
both alpha- and beta-thalassemia is anemia with or without evidence of hemolysis.22 Individuals 
with only one deletion of the four alpha-globin genes generally do not exhibit any adverse 
clinical phenotype; individuals with two alpha-globin deletions, however, may experience 
anemia without hemolysis. Serious complications of thalassemias include infection, osteoporosis, 
and heart and liver disease due to iron overload from receipt of regular blood transfusions.41 The 
presence of alpha thalassemia in individuals with SCT has been shown to modify the 
concentration of sickle hemoglobin in RBCs and exacerbate ischemic-reperfusion injury leading 
to renal disease.42 More recently, renal dysfunction in patients with thalassemia without 
concomitant SCT or SCA has been documented, posited to be caused by hypoxia, anemia and 
iron-mediated toxicity.43,44 In a sample of 216 individuals primarily presenting with variants of 
beta thalassemia, Quinn et al. (2011) documented albuminuria in 59% of patients, as well as 
renal hyperfiltration and hypercalciuria in approximately one-third of patients.45 
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1.1.5 Biologic plausibility underlying hemoglobinopathies and cancer outcomes 
We posit that the mechanisms that trigger sickling and vaso-occlusion in individuals with 
SCD may be responsible for similar processes, at both the tumor and systemic levels, in SCT 
carriers undergoing cancer therapy. In SCD, conditions of low oxygen in the blood (i.e., 
hypoxia) play a central role in the cycle of RBC deoxygenation and sickling, as well as the 
promotion of inflammation and angiogenesis.46,47 For example, despite a lack of systematic 
population-based studies, both animal and case-report evidence suggest that provocation of RBC 
sickling within or near the tumor microenvironment among cancer patients with SCT may be 
related to hypoxia, an adverse tumor feature found in 50-60% of locally advanced solid 
tumors.11,48,49 At the systemic level, a putative mechanism for hypoxic-related induction of 
sickling in the SCT patient with cancer may be the physiologic rigors of systemic chemotherapy, 
general anesthesia admitted during surgery, and local radiotherapy 11,48-51   
It is biologically plausible that RBC sickling is associated with hypoxia and subsequent 
angiogenesis in the tumor microenvironment, resulting in tumor progression and/or reduced 
sensitivity to systemic chemotherapy. In the tumor microenvironment, hypoxia can be caused by 
inadequate blood flow in tissues, an increase in diffusion distances with tumor expansion, and 
reduced oxygen transport capacity of the blood subsequent to anemia.52 Under these conditions, 
hypoxia inducible factors (HIFs) accumulate and activate genes that express protein products 
related to oxygen delivery, angiogenesis, and glycolysis—all of which are related to an increase 
in tumor cell survival, growth, and metastasis.52 In analysis of 40 patients ages 5 to 32 with renal 
medullary carcinoma (RMC), a hypoxic tumor found almost exclusively in young patients with 
SCT, Swartz et al. found diffuse expression of HIF and vascular endothelial growth factor 
(VEGF), a key protein involved in angiogenesis.53   
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In addition to promoting tumor growth and metastasis, hypoxia is also related to direct 
and indirect resistance to radiotherapy and chemotherapy.54  First, many anticancer drugs exhibit 
decreased cytotoxicity at low oxygen concentrations and are therefore less effective within a 
hypoxic tumor microenvironment.55 Second, hypoxia promotes proliferation of cells with 
diminished apoptotic potential, specifically those with p53 mutations.56 Third, poor blood flow 
associated with an impaired vasculature can lead to diminished distribution of chemotherapeutic 
agents into the tumor.55 
In individuals with either SCD or SCT, the molecular mechanism through which 
resistance to malaria occurs is thought to involve a higher rate of heme release from sickled 
versus normal hemoglobin57 which might be of relevance to tumoral hypoxia. Free heme induces 
heme oxygenase-1 (HO-1), responsible for the oxidative degradation of cellular heme.58 HO-1 
overexpression is prevalent in many solid tumors and is associated with reduced sensitivity to 
chemotherapy, advanced disease stage, and poor prognosis.58,59 Promoted by overexpression of 
HO-1, murine melanoma models with SCD experienced accelerated tumor angiogenesis, tumor 
growth, and metastatic potential three weeks after melanoma tumor inoculation compared to wild 
type mice.60 In addition, tumors from SCD mice were marked by frequent microvascular 
occlusion. Terman et al. (2013) demonstrated rapid adherence of sickled RBCs but not normal 
RBCs to tumor vasculature, also characterized by vaso-occulsion.61  
In addition to plausible interactions between hemoglobinopathies and the hypoxic tumor 
microenvironment leading to adverse outcomes in cancer, associations between 
hemoglobinopathies and sub-clinical or clinical comorbid conditions such as renal dysfunction 
and chronic kidney disease may interact to induce adverse cancer outcomes. In individuals with 
SCD, hypoxia-induced sickling in the renal medulla results in a dose-dependent relationship with 
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kidney injury in the form of glomeruloscleriosis and proteinuria.38,62 Naik et al. (2014) observed 
approximately 6% of incident chronic kidney disease was attributable to SCT, with additional 
associations with decline in estimated glomerular filtration rate (eGFR), and albuminuria.38 
Among individuals with transfusion-independent beta-thalassemia, renal dysfunction and disease 
can develop via anemia and increased intestinal iron absorption triggered by ineffective 
erythropoiesis. Chronic hypoxia of tubular cells lead to endothelial and epithelial injury, 
glomerulosclerosis, kidney fibrosis, and an ultimate decline in eGFR.43,44 In cancer patients, 
acute renal failure and chronic kidney disease are associated with survival in patients with 
cancer, through limited ability to withstand aggressive therapies due to dose adjustments in 
chemotherapeutic agents excreted primarily by the kidneys.63,64 
Overall, we hypothesize that the increased physiologic stressors, specifically sustained 
tumor hypoxia and sickling events, in cancer patients with inherited hemoglobinopathies, is 
positively associated with a more malignant cancer phenotype and treatment resistance, 
potentially leading to lower rates of treatment completion, increased rates of adverse events, and 
worse overall survival.  
 
1.1.6 SCT and public health research agenda 
A 2010 workshop of The National Heart, Lung, and Blood Institute (NHLBI) of the NIH 
as well as a 2009 working meeting of CDC via request from the Sickle Cell Disease Association 
of America have provided information and guidelines regarding health implications of SCT, gaps 
in current public health research, and frameworks for future research initiatives.32  Similarly, the 
American Society of Hematology (ASH) recently published a set of sickle cell research priorities 
which included unanswered questions regarding the contribution of SCT to health outcomes.65 
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From a historical perspective, early efforts to conduct sickle cell screening were marred by issues 
of discrimination, stigma, and poor or inadequate counseling.32 In the early 1970s, race-based 
newborn screening programs were instituted in 34 US states, targeting AA/B individuals 
exclusively. In 1981, a young woman in North Carolina brought a federal case against the local 
Burke County Health Department and Department of Social Services after being erroneously 
diagnosed with SCT during a prenatal care visit and coerced to undergo unwanted sterilization.66  
In other instances, individuals with SCT were denied health and life insurance, faced 
employment discrimination, and denied entry into the armed forces.67,68 A lack of public 
awareness combined with inconsistent health education programs persists into the present and 
may often result in messages delivered to SCT carriers and their families that increase stigma 
and anxiety.32 Since 2010, the National Collegiate Athletic Association (NCAA) has required all 
athletes at Division I and II schools to be tested (with an ‘opt-out’ provision for students who can 
show proof of a prior test or who are willing to sign a waiver of liability) for SCT.69 The NCAA 
has worked with the American College of Sports Medicine (ACSM) to formulate guidelines and 
establish a research agenda to study the relationship between physical exertion and SCT, but 
organizations such as ASH have publicly opposed the testing and disclosure of SCT status, 
instead recommending universal interventions for all athletes to reduce exertion-related injury 
and death, following policy implemented by the US Army.70  
Despite the controversy surrounding SCT screening among athletes, universal newborn 
screening for hemoglobinopathies regardless of race has been mandated in all 50 states and the 
District of Columbia since May 1, 2006.71 Beginning with New York in 1975, other states 
gradually adopted universal screening for hemoglobinopathies, but variation continues to exist in 
the types of hemoglobinopathies screened for, the techniques used for screening, and the 
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counseling offered to families. No standardized medical language ontology or data collection 
techniques are integrated across states, and only New York, Texas, Washington, and California 
perform molecular testing as a routine part of their screening protocols.71,72 The staggered and 
non-uniform implementation of universal screening for hemoglobinopathies has resulted an 
estimated 84% of the adult population with SCT and other hemoglobinopathy variants currently 
unaware of their status.73-76 Further, only an estimated 37% of families are notified of SCT from 
newborn screening follow-up, likely due to the fact that many screening programs have no 
protocols for ensuring positive results for SCT are received.76 
Even with the advent of adequate genetic counseling programs, the dearth of information 
available regarding the potential health consequences of SCT will still leave families uncertain 
about best health practices. The NIH, CDC, and ASH have all highlighted the issue of limited 
population-based research assessing adverse health outcomes associated with SCT, and have 
recommended studies that employ databases with sufficient population size to analyze these 
associations.77 From the perspective of cancer outcomes research, it may be appropriate for 
investigations to include all hemoglobinopathies in addition to SCT, since it is possible that 
mechanisms leading to adverse cancer events in patients with SCT may be similar for other 
hemoglobin variants.77 One major unanswered question proposed by ASH is whether 
hemoglobin variants interact with other genes or gene products to ameliorate or worsen other 
conditions65, which can be practically appended to the challenge in cancer therapeutics research 
in determining whether SCT or other hemoglobin variants interact with specific oncogenic 
mutations or exhibit response within malignant tumor environments. 
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1.2 Preliminary Research 
The absence of population-based studies among individuals with hemoglobinopathies has 
made it difficult to confidently predict associations with cancer outcomes. In addition to a 
published collection of case reports documenting an association between SCT and cancer 
outcomes11, Dr. Swede conducted a chart review on a sample of 94 breast cancer patients from 
the Connecticut Tumor Registry (CTR).  
We identified 14 breast cancer patients (12 AA/B versus 2 NHW cases) (1998-2013) 
(ICD-9 codes: 174.x; ICD-O-3 codes: C50.0–C50.9) about whom also was reported a status of 
SCT or SCD (ICD-9 codes: 282.5, 282.60, 282.61, 282.62, 282.63, 282.64, 282.68, 282.69) from 
the Yale-New Haven Hospital system (including the Hospital of Saint Raphael) in Connecticut. 
An age- and race-matched sample of breast cancer patients without a report of sickling 
hemoglobinopathy diagnosis (n = 40 AA/B and n = 40 NHW controls) also was identified. 
Demographic and clinical information was abstracted from each patient’s medical chart, 
including medical history.78 Breast surgery, radiation, and chemotherapy regimens, as well as 
any complications/adverse events related to each treatment also were recorded. Adverse events 
potentially related to SCT were defined as one or more of the following: mild joint pain (diffuse 
or specific), severe joint pain (diffuse or specific), renal insufficiency, renal failure, deep vein 
thrombosis, cerebrovascular event (stroke), emergency room visit, hospitalization, and early 
treatment discontinuation.79,80 
Median follow-up was shorter for AA/B SCT+ cases (46 months) compared to AA/B 
SCT- controls (88 months) and NHW SCT- controls (99 months). Five of 14 SCT+ cases died 
during follow-up (35.7%), compared to 32.5% (n = 13) for AA/B SCT- controls and 15.0% (n = 
6) for NHW SCT- controls. Of the 5 SCT+ cases who died, the cause of death was associated 
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with sickle cell disorder for only 1 patient. A summary of demographic and clinical 
characteristics is provided in Table 1.1. Since this preliminary investigation did not have 
sufficient power to detect true differences if they exist between groups of patients, statistical tests 
of significance were not performed. The proportion of AA/B women who experienced at least 
one adverse event from any treatment (surgery, radiation, chemotherapy) was similar between 
SCT+ and SCT- patients (64.3% and 63.2%, respectively) and nearly 50% higher than in NHW 
SCT- patients (35.9%), as seen in Figure 1.1. 
 A comparison of complications by treatment modality (surgery, radiation, and 
chemotherapy) suggest that a higher proportion of AA/B SCT+ breast cancer patients undergoing 
surgery, radiation, or chemotherapy, respectively, experienced adverse events compared to AA/B 
SCT- and NHW SCT- patients. Of the 12 AA/B SCT+ patients who had surgery, 58.3% (n = 7) 
experienced one or more adverse event, of which 1 was potentially associated with SCT. Of the 
38 AA/B SCT- patients who had surgery, 31.6% (n = 12) experienced one or more adverse 
event, of which 2 were potentially associated with SCT. Of the 38 NHW SCT- patients who had 
surgery, 15.8% (n = 6) experienced one or more adverse event, none of which were potentially 
associated with SCT. 
Of the six AA/B SCT+ that had radiation therapy, 83.3% (n = 5) experienced one or more 
adverse event. Of the 29 AA/B SCT- patients that had radiation therapy, 37.9% (n = 11) 
experienced one or more adverse event (Table 1.2). Of the 25 NHW SCT- that had radiation 
therapy, 12.0% (n = 3) experienced one or more adverse event. No patients experienced an 
adverse event potentially associated with SCT. Of the 8 AA/B SCT+ patients who had 
chemotherapy, 75.0% (n = 6) experienced one or more adverse event, of which 4 were 
potentially associated with SCT. Of the 29 AA/B SCT- patients who had chemotherapy, 58.6% 
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(n = 17) experienced one or more adverse event, of which 3 were potentially associated with 
SCT. Of the 22 NHW SCT- patients who had chemotherapy, 31.8% (n = 7) experienced one or 
more adverse event, 1 of which was potentially associated with SCT. The potential sickling-
related adverse events experienced following surgery and chemotherapy were hospitalization, 
treatment discontinuation, joint pain, and deep vein thrombosis (AA/B SCT+ only, n = 2). 
Overall, a descriptive presentation of results suggests that SCT+ breast cancer patients 
experience a larger proportion of potentially unique complications that carry with them clinical 
implications for treatment protocols.
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1.3 Research Plan 
1.3.1 Conceptual model 
Based on the biologic plausibility of an association between SCT (and potentially other 
hemoglobinopathies) and adverse cancer outcomes, our conceptual model proposes an increase 
in tumor hypoxia among patients with SCT who are diagnosed with cancer. The sustained tumor 
hypoxia resulting from the cycle of RBC deoxygenation and sickling is positively associated 
with an aggressive tumor phenotype and resistance to radiation and chemotherapy, ultimately 
leading to lower rates of treatment completion, increased adverse events, and worse survival 
(Figure 1.2). 
 
1.3.2 Specific Aims 
 In a sample of AA/B patients diagnosed with breast (female only) or prostate cancer 
with diagnosed hemoglobinopathies (AA/B +, n= 371) and a propensity score-weighted sample 
of patients without diagnosed hemoglobinopathies (AA/B -, n= 17,303; NHW-, n= 144,863), we 
pursued the following primary analyses: 
 
Aim 1. Describe demographic and clinical characteristics of the three study groups (AA/B+, 
AA/B-, NHW-) such as age, comorbidities, AJCC 6th edition stage, histology, survival time, and 
treatment received by cancer site (breast, prostate). 
 
Aim 2. Compare treatment completion (yes/no) across the three study groups by cancer site 
(breast, prostate) and stage.  
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Aim 3. Compare rates of specific adverse events (e.g., hospitalization, neutropenia, acute renal 
dysfunction, anemia, deep vein thrombosis, joint pain, cardiotoxicity) across the three patient 
groups after receipt of treatment.  
 
Aim 4. Estimate differences in survival across the three patient groups (all-cause, site-specific, 
and competing-risk mortality). 
 
2.0 Methods 
2.1 Database 
We used patient-level information from Medicare claims linked to population-based 
cancer incidence data from the Surveillance, Epidemiology, and End Results (SEER) Program of 
the National Cancer Institute (NCI). The SEER program collects cancer incidence, vital status, 
and clinicopathological data for patients and tumors from 18 geographic registries covering 
approximately 28% of the US population, including 26% (n = 9,975,844) of the AA/B 
population.81 Contributing to the SEER program are nine states (New Mexico, Hawaii, Utah, 
Iowa, Connecticut, Greater California, Kentucky, Louisiana, New Jersey), five metropolitan 
areas (Metro Atlanta with a  sample of rural Georgia, San Francisco-Oakland and San Jose-
Monterey, Los Angeles, Seattle, Detroit), and the Alaska Native Tumor Registry. The SEER 
program is the gold-standard source of population-based cancer information in the US 
comprising patient demographics, clinical and diagnostic information (primary site, morphology, 
stage at diagnosis), and survival data.81 Vital status for overall and cause-specific mortality are 
reported to SEER by the National Center for Health Statistics.82 Quality control studies 
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(casefinding, reabstracting/recoding, reliability studies) are conducted in SEER areas annually 
and consistently demonstrate a standard for case ascertainment at 98%.82 
Medicare is a federally funded fee-for-service single-payer health insurance program 
available to individuals in the US age 65 or older, people under age 65 with certain disabilities, 
and people with end-stage renal disease (ESRD).83 As is the case in most analyses of SEER-
Medicare data, our investigation is limited to the population 65 years or older because the 
Medicare population under 65 years is not representative of the general population (only 
comprised of disabled individuals and those with ESRD).83 Medicare beneficiaries receive Part 
A hospital insurance which helps cover inpatient care and skilled nursing facilities, as well as 
hospice and home health care. Most Medicare beneficiaries also receive Part B medical 
insurance which helps cover provider services (doctors, nurse practitioners, physical and 
occupational therapists) and outpatient care. Part D prescription drug insurance helps cover 
prescription drug costs, and Part C (Medicare Advantage Plans) coverage consists of private 
health plans (i.e. HMOs) instead of Part A and Part B insurance. All Medicare beneficiaries are 
entitled to Part A hospital insurance, but there are monthly premiums associated with Part B and 
Part D coverage.84 Original Medicare (Part A and Part B) has existed in some form since 1965, 
with the introduction of Part C in 1997, and Part D in 2006.83,84  
The linkage between the SEER program and Medicare (SEER-Medicare) is performed by 
the NCI and the Centers for Medicare and Medicaid Services (CMS) via matching individual 
identifiers (social security number, name, sex, date of birth) in the SEER program to Medicare’s 
master enrollment file.83 The linkage has been completed nine times since 1991 and most 
recently in 2016. Approximately 93% of people 65 years or older identified in the SEER 
program are found in the Medicare enrollment file.83 The full SEER-Medicare database consists 
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of multiple files, one of which is SEER program data while the others are Medicare files. Table 
2.1 provides an overview of the SEER-Medicare data files requested and used for our research.  
The SEER-Medicare database also includes information on a 5% random sample of 
Medicare beneficiaries residing in SEER program areas without a diagnosis of cancer to serve as 
a control group (SUMDENOM file in Table 2.1). Medicare files are available for this control 
group as well as demographic information, and are used in this research to compare comorbidity 
profiles in groups with cancer versus those without cancer.83 
Since SEER-Medicare data are previously collected and de-identified, The University of 
Connecticut Health Institutional Review Board determined that this research did not constitute 
human subjects research and was exempt from review. 
 
2.2 Cohort Selection 
 We identified individuals with a diagnosis of breast (female) or prostate cancer from 
2007 to 2013 for inclusion in this investigation. We chose to restrict analysis to breast and 
prostate cancer because these cancers are the highest incident cancers in both the AA/B and 
NHW populations1 and because they exhibit large and persistent disparities in cancer-specific 
mortality between AA/B and NHW patients.3 We included patients for which female breast or 
prostate cancer was the first or only primary tumor. For breast cancer patients, we included only 
patients with histology consistent with epithelial origin. We included patients age 66 years or 
older in order to calculate comorbidities up to one year prior to cancer diagnosis. The cohort was 
limited to patients with a known month and year of diagnosis, not diagnosed on an autopsy 
report or diagnosis to ensure availability of follow-up information. We also required patients to 
have continuous Part A and B coverage from at least one year before through at least one year 
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after cancer diagnosis; we excluded patients with HMO coverage because no Medicare claims 
are available in the SEER-Medicare database for these patients.83 We constructed three study 
groups based on race and a diagnosis of SCT or other hemoglobinopathy:  
1. AA/B patients with a hemoglobinopathy diagnosis (AA/B+)  
2. AA/B patients with no hemoglobinopathy diagnosis (AA/B-)  
3. NHW patients with no hemoglobinopathy diagnosis (NHW-) 
The complete cohort selection criteria diagrams for breast and prostate cancer are available in 
Appendix A. A total of 163,532 patients met the clinical selection criteria consisting of breast 
(female only) (n = 76,135; 46.6%) and prostate cancer (n = 87,397; 62.2%). Of the breast cancer 
patients, 6,919 (9.1%) were AA/B and 187 (2.7%) were found to have had at least one claim for 
a hemoglobinopathy. Of the prostate cancer patients, 10,755 (12.3%) were AA/B and 184 (1.7%) 
had at least one claim for a hemoglobinopathy. A total of 995 NHW patients (n = 502 breast 
cancer; n = 493 prostate cancer) with a hemoglobinopathy diagnosis were removed from primary 
analyses, but select sensitivity analysis including this group is presented in Appendix D. The 
final sample size for the study cohort was 162,537 patients (n = 75,633 breast cancer; n = 86,904 
prostate cancer). 
 
2.3 Data Elements 
2.3.1 Hemoglobinopathies 
We identified patients in the SEER-Medicare database with an International 
Classification of Disease (ICD-9) diagnostic code for any hemoglobinopathy (ICD-9: 282.4 – 
282.7) over the course of the entire study period (2006-2014) (Table 2.2). A total of 18 distinct 
ICD-9 diagnosis codes were identified as hemoglobinopathies, which were further grouped into 
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four subcategories: sickle cell trait, sickle cell disease, thalassemia, and other 
hemoglobinopathies. 
 
2.3.2 Demographic and clinical covariates 
Patient characteristics incorporated into various analyses included: age at diagnosis, race 
(AA/B or NHW), year of diagnosis (2007 to 2013), geographic residence (SEER registry area), 
urban/rural residence, median household income (measured at the census tract and ZIP code 
levels), education (percentage of adults without a high school degree from census tract and ZIP 
code levels), marital status (married, single, other), and Charlson Comorbidity Index (CCI) 
score85,86 (0, 1, ≥2). Tumor characteristics included in the SEER dataset are: AJCC 6th edition 
stage, tumor size (cm), tumor grade (well differentiated, moderately differentiated, poorly 
differentiated, undifferentiated), Gleason score (prostate cancer only), histological type (ductal, 
lobular, other) (breast cancer only), number of positive lymph nodesiv, estrogen receptor statusv 
(breast cancer only), and progesterone receptor statusvi (breast cancer only). 
 Using a validated macro provided by the NCI, the CCI score was calculated from a 
weighted list of 16 conditions based on their respective hazard ratio of death within 1 year of 
cancer diagnosis87: myocardial infarction, congestive heart failure, peripheral vascular disease, 
cerebrovascular disease, chronic obstructive pulmonary disease, cirrhosis, dementia, paralysis, 
diabetes, diabetes with sequelae, chronic renal failure, moderate to severe liver disease, 
rheumatologic disease, ulcers, connective tissue disorders, and AIDS. The CCI score is 
                                                 
iv Collaborative Stage (CS) Regional Nodes Examined  
v Collaborative Stage (CS) Site-Specific Factor 1 
vi CS Site-Specific Factor 2 
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calculated based on diagnoses for which associated medical claims appears from one year prior 
to cancer diagnosis through one month prior to cancer diagnosis. 
 
2.3.3 Treatment regimen – breast cancervii 
A complete list of diagnosis and treatment codes for breast cancer is available in Appendix B. 
Surgery 
Surgery was defined from Medicare inpatient, outpatient, and carrier claims (ICD-9 
procedure codes and HCPCS codes) for mastectomy or breast-conserving surgery (BCS) 
(including partial mastectomy or lumpectomy) received within six months of initial diagnosis. 
 
Radiation 
 Radiation therapy was defined from Medicare outpatient and carrier claims (ICD-9 
diagnosis and procedures codes, HCPCS codes, revenue center codes91) for external beam 
radiotherapy, intensity modulated radiotherapy, or brachytherapy received within nine months of 
initial diagnosis. 
 
Chemotherapy 
 Chemotherapy was defined from Medicare inpatient, outpatient, carrier, and DME claims 
(ICD-9 diagnosis and procedure codes and HCPCS codes). Time to adjuvant chemotherapy was 
defined as days from the most definitive resection of the primary site to the first administration 
of chemotherapy. Length of adjuvant chemotherapy was defined as the number of months 
between the first and last claims indicating the use of chemotherapy, with the standard length 
                                                 
vii We identified surgery and radiation therapy from both SEER data and Medicare claims88,89 and identified 
chemotherapy from Medicare claims.90 
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defined as 24 weeks or six months. For breast cancer patients with estrogen receptor positive and 
progesterone receptor positive disease, we also identified the use of hormone therapy using 
HCPCS codes.   
 
2.3.4 Treatment regimen – prostate cancer 
A complete list of diagnosis and treatment codes for prostate cancer is available in Appendix B. 
Surgery 
Surgery was defined from Medicare inpatient, outpatient, and carrier claims (ICD-9 
procedure codes and HCPCS codes) for prostatectomy, laparoscopic radical prostatectomy with 
robotic assistance, with or without pelvic lymph node dissection received within 12 months of 
initial diagnosis.   
 
Radiation 
 Radiation therapy was defined from Medicare outpatient and carrier claims (ICD-9 
diagnosis and procedures codes, HCPCS codes, revenue center codes91) for external beam 
radiation, brachytherapy, image-guided radiation, stereotactic radiosurgery, or proton beam 
radiation therapy received within 12 months of initial diagnosis; for men who received surgery, 
receipt of radiation therapy was examined within 12 months of initial diagnosis or within nine to 
12 months of surgery.92,93 
 
Androgen Deprivation Therapy (ADT) 
 ADT was defined from Medicare outpatient and carrier claims (ICD-9 diagnosis and 
procedures codes, HCPCS codes, revenue center codes91) for orchiectomy and gonadotropin-
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releasing hormone (GnRH) agonist received in combination with radiation therapy (within 12 
months of initial diagnosis or within nine to 12 months of surgery). 
 
2.3.5 Outcomes 
Treatment Completion 
 Treatment completion was broadly defined based on National Comprehensive Cancer 
Network (NCCN) guidelines for breast and prostate cancer, respectively.94,95 For stage I or II 
breast cancer, definitive surgical therapy was defined as receipt of BCS or mastectomy within six 
months of initial diagnosis, and receipt of radiation after surgery within nine months of initial 
diagnosis.96 For stage I or II breast cancer patients who received chemotherapy, completion of 
adjuvant chemotherapy was defined as five consecutive months with at least one chemotherapy 
claim.97,98 For Stage III breast cancer, treatment completion was defined as BCS or mastectomy, 
with radiation therapy following surgery, and adjuvant chemotherapy or hormone therapy (same 
guidelines as above). In breast cancer patients with HER2 positive receptor status, receipt of 
trastuzumab (Herceptin) and pertuzumab (Perjeta) was required for treatment to be defined as 
complete.94 For stage IV breast cancer patients, treatment completion was defined as receipt of 
five consecutive months with at least one chemotherapy claim. For stage 0 breast cancer patients 
with ductal carcinoma in situ (DCIS), treatment completion was defined as receipt of BCS or 
mastectomy within six months of initial diagnosis. Breast cancer patients with stage 0 lobular 
carcinoma in situ (LCIS) and patients with unknown stage were excluded from analysis of 
treatment completion. For breast cancer patients who received surgery and who were indicated to 
receive chemotherapy, time from surgery to chemotherapy was calculated for each study group. 
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 For prostate cancer, stage I cancer (T1 or T2a), treatment completion was defined as 
receipt of a prostate-specific antigen (PSA) blood test or prostate biopsy, radiation therapy, or 
prostatectomy within 12 months of initial diagnosis.  For stage II cancer (T2b and T2c), 
treatment completion was defined as receipt within 12 months of initial diagnosis of radical 
prostatectomy with pelvic lymph node dissection or radiation therapy and receipt of ADT. For 
stage III cancer (T3), treatment completion was defined as radical prostatectomy and/or receipt 
of ADT or receipt of radiation therapy, or radical prostatectomy with receipt of PSA testing or 
prostate biopsy. Finally, for stage IV cancer, treatment completion was defined as any 
combination of therapy for stage III, with the addition of ADT therapy alone.95 
 
Adverse Events 
Adverse events were defined as specific clinical complications requiring hospitalization 
known to be associated with hemoglobinopathies including hematuria, renal papillary necrosis, 
acute chest syndrome, anemia, ischemia, thrombocytopenia, hyposthenuria, splenic infarction, 
rhabdomyolysis, hyphema, venous thromboembolism, priapism, leg ulcers, cholelithiasis, and 
stroke.34 We also included other adverse events known to be associated with receipt of 
chemotherapy: infections, fever, nausea, leukopenia, diarrhea, dehydration/electrolyte 
abnormality, malnutrituion, malaise/fatigue, fractures, headaches, pulmonary conditions, 
disorders of lipid metabolism, diabetes, blood transfusion, nephrotoxicity, and cardiac events.99 
In addition, we defined adverse events as those putatively related to sickle cell trait and 
other hemoglobinopathies based on case report evidence up to 12 months after cancer diagnosis. 
Adverse events included emergency room (ER) visits, neutropenic fever, shortness of breath, 
severe chest pain, diffuse body aches, hemiplegia, renal toxicity, hepatic toxicity, hemolysis, 
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severe back pain, myalgia, generalized joint pain, multiorgan failure, respiratory distress, 
hypoxia, dyspnea, mechanical ventilation, pulmonary embolism, vaso-occulsive crisis, and 
mucositis.33,34,79  
A dichotomous indicator was created for each adverse event, and the total number of 
adverse events was calculated for each of the three study groups. A complete list of adverse 
event codes is available in Appendix B. 
 
Mortality and Survival Time 
 Vital status is captured in SEER data and cause of death (COD) was categorized as site-
specific (breast or prostate cancer) or other COD. Survival time was measured from the date of 
diagnosis until death or December 31, 2015 (end of follow-up). For site-specific survival, 
patients were censored if they were alive at the end of the study period or died of causes other 
than breast or prostate cancer, respectively. For competing risks survival, patients were censored 
if they were alive at the end of the study period and considered to have died from a competing 
cause if the cause of death was not breast or prostate cancer. 
 
2.4 Statistical Analysis 
2.4.1 Descriptive analyses 
For each cancer site (breast and prostate), demographic and clinical patient characteristics 
were categorized (see section 2.3.2) and frequency distributions of categorical variables were 
compared in combined analysis using chi-square tests across the three comparison groups: 
AA/B+, AA/B-, NHW-. ANOVA (Kruskal Wallis non-parametric method) was performed for 
continuous variables across the three study groups. 
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2.4.2 Propensity score weighting 
As in any observational study, the demographic, clinical, and treatment characteristics 
among AA/B+, AA/B-, and NHW- patients could be unequally distributed, resulting in a 
selection bias not fully controlled in multivariable ‘adjusted’ analyses.  Hence, three-way 
propensity score weighting was performed for each cancer site (breast, prostate) to create 
similarly situated (i.e. balanced) comparison groups for subsequent estimation of treatment 
completion, adverse events, and survival. The generalized boosted model (GBM), a non-
parametric machine-learning classifier with multiple iterative regression trees (10,000) was used 
to estimate the propensity score for each of the three comparison indicators using the twang 
package and mnps() function in R Studio v3.3.2 (R Foundation for Statistical Computing, 
Vienna, Austria).100 Separate GBMs were fitted to each comparison group and the probability of 
being in the AA/B+ group was estimated, adjusting for the aforementioned demographic and 
clinical characteristics, stratified by treatment completion status (i.e. two separate propensity 
score analyses performed among those who completed treatment and those who did not complete 
treatment; only stratified in estimation of adverse events and survival analysis). Inverse 
probability of treatment weighting (IPTW) was used to calculate the ‘average treatment effect’, 
or the average effect of having a hemoglobinopathy on a particular outcome.100 Covariate 
balance was evaluated graphically (box plots showing the distribution of propensity score by 
group), as well as using the standardized population mean differences of <20% (Appendix C). 
Any imbalanced covariates still remaining after propensity score weighting were evaluated for 
clinical meaning and if differences were determined to be modest, they were included in doubly 
robust estimation.100 
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2.4.3 Power calculation 
Based on the study cohort size of 162,537, with 371 total AA/B+ (nB) patients, the 
sampling ratio for comparisons with 17,303 AA/B- patients (nA) is represented as, 𝑘1 =
𝑛𝐴
𝑛𝐵
=
46.6. The sampling ratio for comparisons with 144,863 NHW- patients (nX) is represented as, 
𝑘2 =
𝑛𝑋
𝑛𝐵
= 390.5.  Assuming a 25% baseline treatment failure rate, 50% baseline adverse event 
rate, and 5% mortality rate, our study will have sufficient power to analyze a range of effect size 
differences in outcomes: 
 1% 5% 10% 15% 25% 50% 75% 
Treatment failure .051 .085 .190 .356 .734 .998 .999 
Adverse event .054 .161 .488 .828 .998 1.00 1.00 
Mortality .030 .061 .124 .219 .472 .930 .997 
 
2.4.4 Estimation of treatment completion 
Receipt of treatment and treatment completion status were compared across study groups 
(AA/B+, AA/B-, NHW-) using chi-square tests. Unadjusted and multivariable modified Poisson 
regression with robust error variance101 was first performed to estimate the relative risk of 
chemotherapy treatment completion across study groups. Adjusted models accounted for 
demographic and clinical covariates (see section 2.3.2). Second, Poisson regression with robust 
error variance using the propensity weighted study cohort was applied to estimate the association 
between hemoglobinopathies and treatment completion. 
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2.4.5 Estimation of adverse events 
Adverse events (yes vs. no) requiring hospitalization were compared across the three 
study groups (AA/B+, AA/B-, NHW-) using chi-square tests. Adverse events were characterized 
individually and, in order to account for small sample size, within each of the three groups: 1) 
adverse events potentially related to hemoglobinopathies based on case report evidence, 2) other 
adverse events potentially related to hemoglobinopathies, and 3) Other adverse events requiring 
hospitalization. Unadjusted and multivariable modified Poisson regression with robust error 
variance was first performed to estimate the relative risk of being hospitalized for any adverse 
event across the study groups. Adjusted models accounted for demographic and clinical 
covariates (see section 2.3.2). Second, modified Poisson regression with robust error variance 
using the propensity weighted study cohort was applied to estimate the association between 
hemoglobinopathies and adverse events, stratified by treatment completion status.  
 
2.4.6 Survival analysis 
The propensity score weighted study cohort was used to generate Kaplan-Meier curves 
for overall, site-specific, and competing risk survival. Cox proportional hazard regression using 
the propensity score weighted study cohort was applied to estimate the association between study 
group and overall-, cancer-specific, and competing risks survival. Patients were required to live 
up to six months after initial diagnosis to allow patients to survive long enough to initiate and/or 
complete treatment. Effect modification of the association between treatment completion and 
mortality by the occurrence of one or more adverse event and by study group was tested to 
investigate the potentially divergent mechanisms across study groups through which treatment 
completion and adverse events were associated with survival. 
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All statistical tests were two-sided with a significance level of α = 0.05. As mentioned in 
section 2.4.2, propensity score weighting was performed in R Studio v3.3.2 (R Foundation for 
Statistical Computing, Vienna, Austria). All other analyses were performed using SAS 9.4 (SAS 
Institute, Inc., Cary, NC). 
 
3.0 Results  
3.1 Study Cohort  
3.1.1 Patient characteristics 
 Of the 162,537 patients included in the analytic sample (Table 3.1), 75,633 (46.53%) 
were breast cancer patients and 86,904 (53.47%) were prostate cancer patients. Median age was 
72 (IQR: 69 to 78) for AA/B+, 72 (IQR: 69 to 78) for AA/B-, and 74 (IQR: 69 to 79) for NHW-. 
A larger proportion of AA/B+ and AA/B- resided in metro areas (88.68% and 87.75%, 
respectively) compared to NHW- (81.43), omnibus p <.001. AA/B+ and AA/B- were more likely 
to be diagnosed with stage IV disease (9.97% and 8.71%, respectively) compared to NHW- 
patients (6.46%, omnibus p <.001). Among breast cancer patients, AA/B+ and AA/B- women 
were more likely to have tumors ≥4 cm, more likely to have poorly differentiated (grade 3) 
tumors, and more likely to have estrogen and progesterone receptor negative tumors compared to 
NHW- women (omnibus p <.001). Among prostate cancer patients, less than 1% of all patients 
(n = 845) had Gleason scores from 2 to 4; 56.09% (n=48,744) had scores from 5 to 7; and, 
36.81% (n=31,990) had Gleason scores from 8 to 10. Significant differences across the three 
study groups were observed for all variables included in Table 3.1.  
When analysis of variables listed in Table 3.1 was restricted to a comparison between 
AA/B+ and AA/B- patients, only two significant differences (data not shown) emerged: SEER 
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Registry Area (p =.008) in that AA/B+ were more likely to reside in the Midwest and less likely 
to reside in the South compared to AA/B-); and, the Charlson Comorbidity Index (CCI) score 
(36.66% of AA/B+ had a CCI score ≥3 compared to 22.97% for AA/B-; p <.001).  
We estimated the prevalence of specific hemoglobinopathies in the analytic study cohort, 
prior to excluding NHW+ patients (n = 995). As seen in Appendix D, the proportion of patients 
with any hemoglobinopathy was 2.10% (n = 371 of 17,674) for AA/B patients and 0.68% (n = 
995 of 145,858) for NHW patients. Overall, the prevalence of every hemoglobinopathy 
disorder/variant was more common among AA/B patients compared to NHW patients. Among 
AA/B patients, SCT was the most prevalent hemoglobinopathy. The prevalence of SCT was 
0.78% (n = 137 of 17,674) for AA/B patients and 0.03% (n = 40 of 145,858) for NHW patients. 
These estimates varied somewhat by cancer type for AA/B patients; the prevalence of SCT was 
1.11% (n = 77 of 6,919) among AA/B breast cancer patients compared to 0.56% (n = 60 of 
10,755) among AA/B prostate cancer patients. The most prevalent hemoglobinopathy among 
NHW patients was “other hemoglobinopathies” comprising hemoglobin C and hemoglobin E 
disease. 
To ensure that the prevalence estimates of hemoglobinopathies in our analytic study 
cohort were not subject to selection bias, we estimated the prevalence of hemoglobinopathies in 
the SEER-Medicare database prior to having applied exclusions to create the analytic study 
cohort (e.g., requirement to be age 66 or older in order to have co-morbidity data in the 
preceding year and continuous fee-for-service coverage from one year prior through one year 
after cancer diagnosis), and found no appreciable difference in prevalence estimates (<0.1% 
difference) (data not shown).  
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The distribution of the CCI score by study group is depicted in Figure 3.1. We found that 
AA/B+ patients had significantly higher mean CCI scores (2.30, 95% CI: 2.08 to 2.52) compared 
to AA/B- patients (1.54, 95% CI: 1.51 to 1.56) and NHW- patients (1.01, 95% CI: 1.00 to 1.02), 
respectively (omnibus p <.001). A larger proportion of AA/B- (37.38%) and NHW- (41.01%) 
patients had no comorbidities diagnosed in the 12 months prior to cancer diagnosis compared to 
AA/B+ patients (22.91%), while a larger proportion of AA/B+ patients had a CCI score of five 
or more (16.44%) compared to AA/B- (7.67%) and NHW- (5.93%) patients (Figure 3.1).   
Regarding specific comorbidities (Table 3.2), statistically significant (all p <.05) 
differences were observed by study group among each of the selected comorbidities (e.g., 
myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular 
disease, chronic obstructive pulmonary disease, dementia, paralysis, diabetes, diabetes with 
sequelae, chronic renal failure, moderate to severe liver disease, ulcers, connective tissue 
disorders, AIDS). When analysis was restricted to comparisons between AA/B+ vs. AA/B- 
patients (Table 3.2), we found that AA/B+ patients were more likely than AA/B- to have a 
history in the 12 months prior to diagnosis of myocardial infarction (2.96% vs. 1.46%), 
congestive heart failure (20.75% vs. 12.60%), cerebrovascular disease (18.06 vs. 13.73%), 
chronic obstructive pulmonary disease (COPD) (23.72% vs. 17.91%), diabetes (55.53% vs. 
38.81%), diabetes with sequelae (22.10% vs. 12.81%), chronic renal failure (25.34% vs. 
14.08%), ulcers (3.50% vs. 1.78%), and connective tissue disorders (6.20% vs. 3.24%). 
 
3.1.2 Treatment receipt 
Receipt of treatment was stratified by tumor site. For breast cancer patients (Table 3.3), a 
total of 65,162 (86.16%) of patients received surgery. Rates of breast-conserving surgery (BCS) 
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were lower among AA/B+ (47.59%) and AA/B- (45.81%) patients compared to NHW- patients 
(57.3%) (omnibus p <.001), but there were no statistically significant differences between 
AA/B+ and AA/B- patients in receipt of surgery or the type of breast surgery, regardless of 
AJCC stage or CCI Score. A similar pattern was observed for radiation therapy, in that both 
AA/B+ and AA/B- were less likely to receive radiation therapy compared to NHW- (44.39% for 
AA/B+, 41.25% for AA/B-, 50.12% for NHW-, omnibus p <.001), yet no statistically significant 
difference was observed between AA/B+ and AA/B-. The rate of receipt of any chemotherapy 
was slightly higher among AA/B+ (31.02%) and AA/B- (29.96%) breast cancer patients 
compared to NHW- (25.87%) patients (omnibus p <.001), but again, no significant differences 
emerged between AA/B+ and AA/B- patients. Less than 5.0% of patients within each study 
group received neoadjuvant chemotherapy.  
Among prostate cancer patients (Table 3.4), a total of 61,760 (71.07%) patients received 
initial curative therapy, defined as receipt of prostatectomy, radiation, ADT, or chemotherapy 
within 180 days of diagnosis. AA/B- were less likely than NHW- to receive initial curative 
therapy (67.51% vs. 71.56%, respectively, p <.001), but rates for AA/B+ (70.11%) did not differ 
significantly from the other two study groups. A total of 16,561 (19.06%) of patients received 
prostatectomy (including laparoscopic radical prostatectomy with robotic assistance). Rates of 
surgery were significantly higher in AA/B- (13.59%) and AA/B+ (12.21%) compared to NHW- 
(20.02%) (p <.001), but there was no statistically significant difference between AA/B+ and 
AA/B- patients. No significant differences in receipt of radiation therapy were observed between 
the study groups (p =.53).  Overall, 29,699 (34.17%) prostate cancer patients received ADT 
within 12 months of diagnosis; AA/B- were slightly more likely to receive ADT compared to 
NHW- (35.99% vs. 33.91%, respectively, p <.001), but AA/B+ patients (39.67%) did not differ 
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significantly in receipt of ADT compared to the other two study groups. Finally, the rate of 
receipt of chemotherapy within 12 months of diagnosis was significantly higher among AA/B+ 
(42.93%) and AA/B- (37.14%) compared to NHW- (35.32%) (p =.03 and p <.001, respectively), 
but again, no significant differences emerged between AA/B+ and AA/B- patients (p =.10).   
 
3.2 Treatment Completion 
Of the 75,633 breast cancer patients included in the study cohort, a total of 71,078 
(93.98%) patients had sufficient data on stage at diagnosis to determine whether treatment was 
completed based on NCCN guideline criteria. For prostate cancer, a total of 81,325 (93.58%) 
patients had sufficient data on stage at diagnosis to determine whether treatment was completed 
based on NCCN guideline criteria. Therefore, a total of 152,403 patients were evaluated for 
treatment completion by stage.  
Among breast cancer patients, AA/B+ and AA/B- patients had lower rates of treatment 
completion compared to NHW- (44.38% vs. 45.40% vs. 52.84%, respectively, omnibus p <.001) 
(Table 3.5). This pattern remained consistent when treatment completion was stratified by stage. 
Stage II breast cancer AA/B+ patients were marginally less likely than AA/B- stage II breast 
cancer patients to complete treatment (22.92% vs 34.81%, p = .08). Cell sizes <11 for AA/B+ 
with stage III and stage IV breast cancer prevented comparison with AA/B- and NHW- patients.  
Among prostate cancer patients, AA/B+ and AA/B- patients had slightly lower overall 
rates of treatment completion compared to NHW- (75.74% vs. 74.90% vs. 77.46%, respectively, 
omnibus p <.001), driven by the high completion rates in patients with stage I (T1 and T2a) 
disease (Table 3.6). For stage II cancer, AA/B+ and AA/B- patients were less likely to complete 
treatment compared to NHW- (37.04% vs. 33.47% vs. 43.52%, respectively, omnibus p <.001).  
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Cell sizes <11 for AA/B+ with stage III and stage IV breast cancer prevented comparison with 
AA/B- and NHW- patients, but AA/B- experienced dramatically lower rates of treatment 
completion compared to NHW- patients (stage III AA/B-: 43.37% vs. NHW-: 64.75%, p <.001; 
stage IV AA/B-: 59.40% vs. NHW-: 71.92%, p <.001). 
Table 3.7 displays the unadjusted and adjusted (both multivariable adjusted and 
propensity score weighted) relative risk of incomplete treatment by study group for all patients 
and stratified by tumor site. In unadjusted analysis, AA/B+ and AA/B- breast cancer patients had 
significantly higher risk of incomplete treatment compared to NHW- patients; this effect 
remained significant among AA/B- patients in multivariable adjusted analysis (RR: 1.05, 95% 
CI: 1.043 – 1.08, p <.001), but was attenuated and did not remain significant in propensity score 
weighted analysis (RR: 1.01, 95% CI: 0.96 – 1.05, p = .82). Pairwise comparisons between 
AA/B+ and AA/B- patients revealed no significant differences in adjusted risk of treatment 
completion, overall or by tumor site (data not shown).   
  AA/B- prostate cancer patients were significantly less likely to complete treatment 
compared to NHW- patients in unadjusted, multivariable adjusted, and propensity score 
weighted analysis (propensity score weighted RR: 1.17, 95% CI: 1.12 – 1.22, p <.001), but no 
statistically significant differences in risk of incomplete treatment were observed between 
AA/B+ vs. NHW- patients (Table 3.7). Pairwise comparisons between AA/B+ and AA/B- 
patients revealed no significant differences in adjusted risk of treatment completion, overall or by 
tumor site (data not shown).   Details and diagnostic assessment of the propensity score weighted 
analysis are presented in Appendix C.
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3.3 Adverse Events 
Patients who received treatment were evaluated for the incidence of adverse events 
requiring hospitalization during follow-up (Table 3.8). A total of 69,531 (91.9%) breast cancer 
patients and 65,505 (75.4%) prostate cancer patients received treatment after cancer diagnosis, 
defined as receipt of any surgeryviii, radiation, chemotherapy, hormone therapy, or ADT. Over 
half of the breast cancer patients who received no treatment were diagnosed as stage IV or with 
unknown stage, and approximately 60% of the prostate cancer patients were received no 
treatment were diagnosed as stage I (T1 or T2a), where watchful waiting or active surveillance 
(PSA test and/or prostate biopsy) is recommended, particularly for older patients with expected 
survival <20 years.95  
Overall, 89,479 treated patients (66.26%) experienced at least one adverse event 
requiring hospitalization; nearly half of all treated patients had an emergency room visit (n = 
64,165; 47.52%). Of the 81,797 patients who received surgery, 9,969 (12.19%) experienced an 
adverse event within 90 days; AA/B+ (15.64%) and AA/B- (14.37%) patients were more likely 
to experience an adverse event following surgery compared to NHW- (11.99%) patients 
(omnibus p <.001), but there was no significant difference between AA/B+ and AA/B- patients 
(p= .63). A similar trend was observed for adverse events occurring within 6 months following 
receipt of chemotherapy or ADT (Table 3.8). When adverse events were categorized into three 
groups (known associations with hemoglobinopathies, putative associations with 
hemoglobinopathies, known toxicity associated with cancer therapy) (Table 3.8, Figure 3.2), we 
observed that AA/B+ had a significantly higher proportion of adverse events in all three 
categories compared to both AA/B- and NHW- patients (each p <.001). In addition, AA/B+ 
                                                 
viii Breast cancer: receipt of BCS or mastectomy within 6 months of diagnosis; Prostate cancer: receipt of 
prostatectomy within 12 months of diagnosis. 
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patients had a significantly higher proportion of emergency room visits compared to NHW- 
patients, and a marginally significantly higher proportion of emergency room visits compared to 
AA/B- patients (p =.065).  
 Among all treated patients, AA/B+ had increased propensity score weighted risk of 
experiencing one or more adverse event compared to both AA/B- (RR: 1.15, 95% CI: 1.07 – 
1.24, p <.001) and NHW- (RR: 1.18, 95% CI: 1.10 – 1.26, p <.001) (Table 3.9). The magnitude 
and significance of this relationship was similar for breast and prostate cancer patients (Table 
3.9). 
Among breast cancer patients who completed treatment (Table 3.10), the risk of 
experiencing one or more adverse event requiring hospitalization or an emergency room visit 
was 1.18 times higher for AA/B+ patients vs. NHW- (multivariable adjusted 95% CI: 1.06 – 
1.32, p =.002; propensity score weighted 95% CI: 0.98 – 1.42; p=.084). Likewise, AA/B+ 
patients also were 1.17 times more likely than AA/B- to have experienced an adverse event 
requiring hospitalization or ER visit (multivariable adjusted 95% CI: 1.05 – 1.31, p =.004; 
propensity score weighted 95% CI: 0.97 – 1.41, p=.098). In contrast, no significant differences in 
risk of hospitalization were observed between AA/B- and NHW- patients. 
For prostate cancer patients who completed treatment (Table 3.10), a statistically 
increased risk of an adverse event requiring hospitalization or ER visit was observed in all 
analyses for AA/B+ patients compared to NHW- and AA/B- patients. Specifically, the 
propensity score weighted risk of experiencing one or more adverse events was 1.22 times 
greater for AA/B+ vs. NHW- (95% CI: 1.09 – 1.36, p <.001). The propensity score weighted risk 
of experiencing one or more adverse events was 1.17 times greater for AA/B+ vs. AA/B- (95% 
CI: 1.06 – 1.31, p =.003) for prostate cancer patients who completed treatment. AA/B- patients 
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were at small but significantly increased risk for adverse events compared to NHW, in both 
propensity score weighted (RR: 1.04, 95% CI: 1.01 – 1.07, p =.020) and multivariable adjusted 
(RR: 1.05, 95% CI: 1.03 – 1.07, p <.001) analysis.  
Among breast cancer patients who did not complete treatment (Table 3.11), AA/B+ 
patients had increased propensity score weighted risk of adverse events compared to both NHW- 
(RR: 1.14, 95% CI: 1.01 – 1.26, p =.018) and AA/B- (RR: 1.13, 95% CI: 1.02 – 1.25, p =.024) 
patients.  No statistically significant differences were observed between AA/B- and NHW- 
patients in adjusted analysis.  
Among prostate cancer patients who did not complete treatment (Table 3.11), AA/B+ 
patients had increased multivariable adjusted risk of adverse events compared to both NHW- 
(RR: 1.18, 95% CI: 1.06 – 1.31, p =.002) and AA/B- (RR: 1.15, 95% CI: 1.03 – 1.28, p =.009), 
but these effects did not remain statistically significant in propensity score weighted analysis. No 
statistically significant differences were observed between AA/B- and NHW- patients in adjusted 
analysis. 
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3.4  Survival 
3.4.1 Mortality and Kaplan-Meier Survival Curves 
Median follow-up time was 53 months (IQR: 33 - 77) and 59 months (IQR: 37 - 82) for 
breast and prostate cancer patients, respectively. Of those surviving to the end of the study 
period, median follow-up time was significantly different across study groups in both cancer 
sites. That is, for surviving breast cancer patients, median follow-up time was 59.5 months (IQR: 
45 to 85) for AA/B+, 60 months (IQR: 40 to 81) for AA/B-, and 62 months (IQR: 42 to 83) for 
NHW-. For corresponding prostate cancer patients, median follow-up time was 68 months (IQR: 
47 to 88) for AA/B+, 65 months (IQR: 46 to 86) for AA/B-, and 67 months (IQR: 47 to 88) for 
NHW-. It is unlikely that differences in follow-up time among surviving patients across study 
groups represent clinically meaningful difference in the adequacy of the follow-up time. 
Regarding mortality among breast cancer patients, 57 AA/B+ (30.48%), 6,732 AA/B- 
(36.41%), and 19,230 NHW- (27.99%) patients died during the study period (omnibus p <.001) 
(Table 3.12). AA/B- were more likely to die from both breast cancer and competing causes 
compared to NHW (p <.001), but no significant differences were observed between AA/B+ and 
NHW- or between AA/B+ and AA/B-. Overall, 2-year and 5-year survival differed only between 
AA/B- and NHW- patients (Table 3.12).   
Among prostate cancer patients (Table 3.12), a total of 75 AA/B+ (40.76%), 3,310 
AA/B- (31.31%), and 19,507 NHW- (25.62%) patients died during the study period (omnibus p 
<.001). Furthermore, pairwise comparisons revealed that the rate of AA/B+ mortality was higher 
than both AA/B- (p =.006) and NHW- (p <.001) groups. Regarding cause-specific death, 
proportionately more AA/B+ patients died from prostate cancer (n = 17, 9.24%) compared to 
NHW (n = 4,201, 5.52%, p =.004) and AA/B- patients (n= 783, 6.98%), but the AA/B+ vs. 
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AA/B- difference did not reach statistical significance (p =.10). Similarly, proportionately more 
AA/B+ patients died from other causes (n = 58, 31.52%) compared to NHW (n = 15,306, 
20.10%), p <.001) and AA/B- patients (n= 2,572, 24.33%, p =.013). 
Two-year and 5-year survival rates (Table 3.12) were significantly higher (all p <.001) 
among NHW- prostate cancer patients (2-year: 92.74%, 5-year: 79.90%) compared to both 
AA/B- (2-year: 90.06%; 5-year: 74.59%, respectively) and AA/B+ patients (2-year: 87.43%, 5-
year: 67.95%, respectively). In contrast, no statistically significant differences were observed 
between AA/B+ and AA/B- patients. Unadjusted and propensity score weighted Kaplan-Meier 
curves illustrating the aforementioned 2-year and 5-year survival patterns per outcome (i.e., all-
cause, cancer-specific, and non-cancer deaths) are presented for breast cancer (Figure 3.3) and 
prostate cancer (Figure 3.4).  
 
3.4.2  Cox Proportional Hazards Survival Analyses 
The propensity scores generated for use in Cox proportional hazards models included 
demographic characteristics (age, year of diagnosis, marital status, SEER region, income, and 
education) as well as stage, CCI score, and number of positive lymph nodes. For breast cancer 
patients, additional covariates were tumor grade, tumor size, histology, estrogen receptor status, 
progesterone receptor status, and HER2 receptor status. For prostate cancer patients, the 
propensity score model included Gleason score.  
While the propensity score weighted hazards models failed to reveal significant 
differences in mortality risk across study groups, the magnitude of the associations with 
mortality in relation to either treatment completion (no vs. yes) or adverse events (≥1 vs 0) 
significantly varied by hemoglobinopathy status  Specifically, as depicted in Figure 3.5, the risk 
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of mortality among AA/B+ patients was 1.29 (95% CI: 1.23 – 1.36, p <.001) times greater 
among those who failed to complete treatment compared to those who completed treatment, yet 
the relative difference in mortality was greater in both AA/B- and NHW- groups (HR: 2.05, 95% 
CI: 1.96 – 2.15, p <.001); HR: 2.32, 95% CI: 2.22 – 2.43, p <.001; respectively).  
Regarding adverse events and mortality (Figure 3.6), the risk of mortality among AA/B+ 
patients was 4.78 (95% CI: 4.23 – 5.41, p <.001) times greater among patients experiencing one 
or more adverse event compared to those who did not experience an adverse event. Unlike the 
trend for treatment completion analyses, however, the adverse event-mortality effect was 
attenuated significantly among both AA/B- (HR: 3.28, 95% CI: 3.06 – 3.51, p <.001) and NHW- 
patients (HR: 3.16, 95% CI: 2.96 – 3.37, p <.001). Compared to NHW-, AA/B+ had a 1.13 (95% 
CI: 1.08 – 1.18) times higher risk of mortality if they completed treatment and experienced 1 or 
more adverse event. Compared to AA/B-, AA/B+ had a 1.11 (95% CI: 1.06 – 1.16) times higher 
risk of mortality if they completed treatment and experienced 1 or more adverse event.  
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4.0 Discussion 
4.1 Summary of Key Findings 
In this retrospective cohort study of patients diagnosed with breast (female) and prostate 
cancer from 2007 to 2013 in the SEER-Medicare linked database, we found that AA/B patients 
diagnosed with hemoglobinopathies experienced higher rates of adverse outcomes compared to 
similarly situated AA/B and NHW cancer patients not diagnosed with hemoglobinopathies. 
Specifically, we found that compared to AA/B- and NHW- patients, AA/B+ patients experienced 
increased risk of one or more adverse event requiring hospitalization following treatment 
initiation, and the risk of mortality was significantly higher among AA/B+ patients who 
experienced one or more adverse event compared to AA/B- and NHW- patients who experienced 
one or more adverse event. 
We observed significant differences across patient, clinical, and tumor characteristics by 
study group, but apart from SEER region and CCI score, these differences were driven by race; 
AA/Bs, regardless of hemoglobinopathy status, were more likely to be diagnosed with cancer at 
younger ages (66 – 74), reside in a metro area, have a lower median household income, not 
married, and diagnosed with stage IV disease. Among breast cancer patients, AA/Bs had larger 
tumors ≥4 cms (breast cancer), poorly differentiated grade tumors (breast cancer), and had higher 
proportions of estrogen and progesterone receptor status negative cancers.  
The observed differences between AA/B+ and AA/B- revealed that AA/B+ patients were 
more likely to reside in the Midwest and less likely to reside in the South compared to AA/B- 
patients. In addition, AA/B+ patients had a significantly lower proportion of CCI scores of 0, and 
significantly higher proportion of scores of 4 and 5 or more, compared to NHW- and AA/B-. 
When differences in individual comorbidities were compared across study groups, myocardial 
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infarction, congestive heart failure, diabetes, diabetes with sequelae, chronic renal failure, and 
ulcers were significantly more common not only among AA/B+ compared to NHW-, but among 
AA/B+ compared to AA/B- as well. When differences across comorbidities were further divided 
across specific hemoglobinopathy groups (SCT, SCD, thalassemia, other), we found that SCT 
was primarily responsible for the observed group differences. Finally, NHW patients who 
appeared in the dataset as having a hemoglobinopathy (NHW+) did not follow the same trend 
(Appendix D).  
While no statistically significant differences were found in the adjusted risk of treatment 
completion between AA/B+ cancer patients compared to NHW- or AA/B- patients, respectively, 
we found that AA/B- prostate cancer patients had an estimated 17% increased risk (95% CI: 12% 
to 22%, p <.001) of incomplete treatment compared to NHW- patients. It is possible that the 
AA/B+ study group lacked the statistical power needed to detect a true effect if it existed. 
Irrespective of power considerations, no statistically nor clinically meaningful differences 
emerged between AA/B+ vs. AA/B- in regards to treatment completion, which could reflect 
actual clinical practice, or could be an artifact of how treatment completion was defined in our 
analysis. 
The overall proportion of adverse events requiring an emergency room visit or 
hospitalization experienced among patients who initiated treatment was significantly higher 
among AA/B+ compared to both NHW- and AA/B-. Approximately 28% of all AA/B+ patients 
experienced 3 or more adverse events, compared to only 15% and 13% in AA/B- and NHW-, 
respectively. In addition, AA/B+ patients were significantly more likely to experience adverse 
events known or putatively known to be associated with hemoglobinopathies as well as other 
chemotherapy-related adverse events. The adjusted risk of experiencing one or more adverse 
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event was approximately 14% higher for AA/B+ compared to both AA/B- and NHW- breast 
cancer patients who failed to complete treatment; while this effect was not significant among 
prostate cancer patients who failed to complete treatment, a 17% and 22% increased risk of one 
or more adverse event was observed for AA/B+ prostate cancer patients who did complete 
treatment compared to AA/B- and NHW- patients, respectively. The relative risk of adverse 
events was marginally increased among AA/B+ compared to AA/B- and NHW- breast cancer 
patients who completed treatment (17% and 18%, respectively). When the requirement for 
having initiated treatment was removed and adverse events were explored in the entire study 
population (n = 162,537), AA/B+ had 17% increased risk of experiencing one or more adverse 
event compared to NHW- (95% CI: 10% to 26%, p <.001) and a 15% increased risk compared to 
AA/B- (95% CI: 8% to 24%, p <.001). This effect remained consistent when adverse events were 
isolated to inpatient hospitalizations, suggesting that AA/B+ cancer patients are not only more 
likely to experience a larger proportion of adverse events, but also more severe adverse events 
compared to AA/B- and NHW- patients across the entire spectrum of cancer care. 
To test the underlying assumption that adverse events were treatment-related and not just 
due to existing comorbidities or an unobserved confounding factor, we examined the risk of 
adverse events, stratified by CCI score (Figure 4.1). Among patients with no comorbidities, 
AA/B+ patients experienced 35% increased risk of experiencing one or more adverse event 
compared to NHW- (95% CI: 15% to 60%). This trend was attenuated (e.g., 18% (95% CI; 6% 
to 30%) for CCI=1; 26% (95% CI: 16% to 38%) for CCI=2; 6% (1% to 28%) for CCI=3; 4% 
(1% to 14% for CCI=4), but remained significant across CCI Scores, and was proportionately 
higher than the association between AA/B- compared to NHW- across CCI Scores from 0 to 2. 
(Figure 4.1).  
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In propensity score weighted survival analysis, no apparent overall survival differences 
emerged between AA/Bs (independent of hemoglobinopathy status) and NHW-. When we 
explored potential factors through which each study group experienced mortality, however, 
treatment completion and adverse events were identified as significant effect modifiers. 
Specifically, while patients in all three study groups who experienced at least one adverse event 
were far more likely to die compared to those with no reported events, the relative difference in 
mortality was highest within the AA/B+ patient group. In contrast, when comparing mortality 
risk among AA/B+ patients who did not complete treatment versus those who did, the relative 
difference was the lowest among the three study groups. A coherent explanation for these 
divergent patterns of effect modifications might be that while AA/B+ patients might be just as 
likely to fail to complete treatment as AA/B- and NHW- patients, the specific reasons for 
discontinuation among AA/B+ patients confer a greater risk of mortality. By extension, we posit 
that the higher risk of AA/B+ patients to experience one or more adverse events suggests that 
these events are comparatively deadlier to AA/B+ compared to AA/B- and NHW- patients. Our 
findings suggest, therefore, that occurrence of an adverse event poses a more serious threat to 
mortality than does not completing treatment. 
 This interpretation also is supported by the variation in the magnitude of the interaction 
between treatment completion and adverse events across the study groups (Figure 4.2). Among 
AA/B+ patients who completed treatment, those who experienced one or more adverse events 
had more than five times the risk of dying than those for whom there were no reports of adverse 
events whereas the estimated relative risks of mortality among AA/B- and NHW- patients were 
about three-fold. Among patients who failed to complete treatment, however, the relative risks of 
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mortality for patients experiencing one or more adverse events was similar across groups (HRs 
of 2.64 to 3.28 with overlapping 95% CIs.  
 
4.2 Consistency with Existing Evidence and Biologic Plausibility 
This research presents the first observational, population-based study investigating the 
association between inherited hemoglobinopathies and cancer outcomes, and as such there is 
limited existing evidence to compare for consistency. On a broad scale, studies investigating 
racial disparities in cancer outcomes can be used as a benchmark to compare the magnitude of 
treatment completion, adverse events, and survival outcomes. Our results can also be put into 
context with other observational studies measuring the impact of SCT and other 
hemoglobinopathies on a variety of chronic conditions and diseases including chronic kidney 
disease38, stroke39, and pulmonary embolism40. Existing evidence for the association between 
hemoglobinopathies and cancer outcomes is limited to a collection of case reports published by 
Swede et al. in 201411 and the preliminary chart review conducted using the CTR (See Section 
1.2). Our results are consistent with case report evidence among patients with SCT, SCD, and 
other combinations of hemoglobin variants who were diagnosed with cancer and receiving 
therapy, which revealed instances of painful crises and other adverse effects requiring 
hospitalization including neutropenia, pulmonary embolism, renal toxicity, respiratory distress, 
and multi-organ failure. Our results are also consistent with findings from a preliminary chart 
review in breast cancer patients undergoing treatment which suggested that women with SCT 
experienced a higher proportion of total adverse events compared to women without SCT.  
The biologic mechanisms underlying the association between hemoglobinopathies and 
cancer-related adverse events are not well defined, but we propose that cancer patients with 
inherited hemoglobinopathies, particularly SCT, are at increased risk for adverse events when 
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exposed to physiologic stressors. Stressors in the form of existing tumor hypoxia, surgery, 
radiotherapy, or systemic chemotherapeutic agents may lead to RBC sickling, vaso-occulsive 
crises, and a host of additional complications.  Evidence from case reports and in vivo animal 
studies suggest that intravascular sickling within the tumor microenvironment may be promoted 
by acidosis and results in increased hypoxia. Sickle cells are considered in the literature as a site-
specific contrast agent due to their propensity to preferentially accumulate in the tumor 
vasculature through impaired blood flow and oxygenation, but this may ultimately result in 
vascular hemolysis, vaso-occulsion, and further hypoxia and organ damage.102 Via upregulation 
of HIF-1, hypoxia induces expression of genes that drive tumor growth (by promoting 
angiogenesis), proliferation, and metastatic potential.103 Pretreatment tumor hypoxia is a known 
prognostic factor for survival after treatment with radiation alone or in combination with surgery 
or chemotherapy, and combined treatments are demonstrably less effective in hypoxic tumors.104 
From a mechanistic perspective, hypoxia confers treatment resistance by inhibiting apoptosis and 
producing quiescent, stem-cell like cell fractions least affected by anticancer treatments targeting 
rapidly proliferating cells. In addition to disrupting the cellular environment, the hypoxic 
microenvironment facilitates tumor growth via angiogenesis, leading to suppression of anti-
tumor immune cells and escape from immune surveillance.103  Multiple studies have found 
sickled RBCs target the hypoxic tumor vascular microenvironment and subsequently include 
vaso-occlusion, autohemolysis leading to endothelial injury.60,61 In a small study comparing 10 
SCD vs. 10 wild-type mice, the tumor growth rate was accelerated in SCD mice compared to 
wild-type, enhanced by HO-1 activity and angiogenesis.60   
In addition to tumor hypoxia, we propose the associations between hemoglobinopathies 
and other conditions including chronic kidney disease, diabetes, and pulmonary embolism play a 
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role in the occurrence of adverse events requiring hospitalization among cancer patients. While 
our results suggested that AA/B+ have increased risk of adverse events compared to NHW-and 
AA/B- across CCI scores, there is evidence to suggest that the specific type of comorbidity may 
impact outcomes. For example, the prevalence of comorbid diabetes in our study was 
significantly higher among AA/B+ (55.5%) compared to AA/B- (38.8%) and NHW- (24.3%). In 
the epidemiological literature, diabetes has been found to be associated with significantly higher 
all-cause mortality across all types of cancer, and higher cancer-specific mortality in patients 
diagnosed with cancer of the breast, endometrium, and colorectum.105,106 The association 
between diabetes and cancer mortality persists even after adjustment for age, BMI, physical 
activity, and other dietary factors.107 From a biological perspective, the association between 
diabetes and cancer mortality could be explained indirectly via the shorter overall life expectancy 
among individuals with diabetes.108 More direct associations include hyperglycemia, and to a 
lesser extent, impaired immune function and/or pro-inflammatory conditions, known to be 
associated with tumor cell proliferation and survival.107,109  
 In addition to diabetes, recent observational studies have documented independent 
associations between SCT and chronic kidney disease38, stroke39, ESRD37, and pulmonary 
embolism40. Among patients with no comorbidities in our study, we found that the risk of 
experiencing a pulmonary embolism or venous thromboembolism was significantly higher 
among AA/B+ compared to both AA/B- and NHW-, but did not find any significant increase in 
the risk of renal failure or stroke in AA/B+ compared to AA/B- or NHW-. We did find, however, 
that AA/B+ had an increased risk of heart failure and other cardiovascular complications, as well 
as anemia, pain, respiratory dysfunction, and emergency room visits compared to AA/B- and 
NHW- (Appendix D). A recent meta-analysis of 4 different US population-based cohorts 
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concluded that the presence of SCT was not associated with an increased risk of heart failure or 
alterations in cardiac structure or function110, so further investigation may be warranted to better 
understand the relationship between hemoglobinopathies and cardiovascular-related events in the 
context of cancer. For thromboembolism, the coagulation pathway is activated by elevated levels 
of d-dimers and monocytes in SCT carriers, which in turn poses an increased risk of vaso-
occlusive crises among patients with sickle cell disease.111 Dirix et al. (2002) found that plasma 
levels of d-dimers are associated with cell proliferation and tumor growth, metastatic potential, 
and shorter overall survival in breast cancer patients. Our results provide indirect evidence to 
support the association between hemoglobinopathies and thromboembolism in the setting of 
cancer, and suggest that the development of thrombosis may reflect the presence of a 
biologically more aggressive cancer that in turn leads to a worse prognosis. Further exploration 
into the potential pathways through which SCT and thromboembolism interact to impact cancer 
outcomes may be important for understanding the overall burden of thrombosis in cancer, given 
that cancer patients account for 20% of all patients with venous thromboembolism and 
thrombosis is believed to account for 9% of all cancer-related deaths.112  
 
4.3 Strengths and Limitations 
The utilization of SEER-Medicare database is the greatest strength of this study, as it is a 
population-based cancer database that contains information on hemoglobinopathy diagnosis from 
medical claims. Data from SEER has the benefit of very low loss to follow-up and contains 
detailed tumor characteristics and cause of death. The Medicare database provides a near 100% 
linkage to individuals appearing in the SEER program, which increases the external validity of 
the study in regards to generalizability of the results to the US elderly population.   
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The primary limitation regarding the use of administrative claims to identify 
hemoglobinopathies is the potential for misclassification bias; in the general population, many 
individuals with hemoglobinopathy variants, particularly SCT, are unaware of their status. This 
is reflected in the low prevalence of SCT and other hemoglobinopathies in our study cohort, 
particularly for AA/B (1.74% for hemoglobinopathies; 0.63% for SCT), where the population 
prevalence is estimated to be approximately 8% and has been confirmed in other observational 
studies investigating the association between SCT and health outcomes.38  Further, it is likely 
that a proportion of patients in our study were incorrectly classified as not having a 
hemoglobinopathy, since diagnosis depended on having a claim for the condition. This 
limitation, however, would bias our comparisons between AA/B+ and AA/B- study groups 
towards the null.  
Another limitation in this observational study is the potential for selection bias and 
confounding by unobserved variables such as performance status (e.g. activities of daily living 
status, functional status, and patient quality of life) used to summarize ability of a patient to 
tolerate aggressive treatment, current smoking status, body mass index, various metabolic 
functions, and treatment dose adjustments. For example, it is possible that patients with 
hemoglobinopathies and associated conditions (i.e. renal failure) are subject to more dose 
adjustments during cancer therapy compared to patients without hemoglobin variants113, which 
could bias results either away from or towards the null. Based on our hypothesis that increased 
tumor hypoxia is the primary mechanism through which patients with hemoglobinopathies 
experience worse clinical outcomes, another important limitation of this study is the absence of 
tumor hypoxia assessment. Since our diagnosis data are based on administrative claims, it is 
likely that we underestimated comorbidities even though we captured comorbidity claims during 
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the 12 months prior to diagnosis.  Our study was also limited to individuals ages ≥66 and those 
with continuous Medicare Part A and B/non-HMO coverage, potentially limiting the overall 
generalizability of results to the entire older adult population, although there is evidence to 
suggest comparable diagnosis and treatment characteristics between managed care and fee-for-
service plans.114  
Finally, this study lacked adequate sample size and power to investigate the association 
between hemoglobinopathies and adverse cancer-related outcomes in individuals with genetic 
ancestry other than AA/B and NHW, specifically individuals with Southeast Asian and Middle 
Eastern ancestry. The increase among immigrant populations in the US from Asian and Arab 
countries with high prevalence of hemoglobinopathies suggest our results may be applicable to 
other races, but our study did not have sufficient sample size to perform these analyses. Further, 
in many studies that deliberately investigate cancer outcomes in racial minorities, Asian 
populations are often grouped together, potentially masking certain effects that could be 
associated with hemoglobinopathies. A recent SEER study found that South Asian and "other 
Asian" (Asian Indian, Pakistani, Filipino, Thai, Vietnamese, Laotian) women exhibit more 
aggressive breast cancer, similar to the magnitude experienced by AA/Bs, when compared to 
Japanese Asian groups.13  
 
4.4 Future Research Directions 
The present study has documented the clinical profile of AA/B+ cancer patients in 
comparison to AA/B- and NHW- patients as well as revealed associations between 
hemoglobinopathy status and treatment completion, adverse events, and mortality. Given the 
nature of observational data analysis, in combination with the relatively limited existing research 
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into the association between hemoglobinopathies and adverse cancer outcomes, our results have 
generated additional hypotheses for future exploration. The framework for our interpretation was 
based on hypothesis-driven results suggesting that AA/B+ status and the occurrence of adverse 
events acted to modify the effect of treatment completion on mortality. Specifically, we observed 
that AA/B+ patients who completed treatment had proportionately increased risk of death 
compared to those who failed to complete treatment. This exaggerated effect was not observed in 
AA/B- or NHW- patients. Furthermore, the increased risk of death for AA/B+ who completed 
treatment also was increased among patients who experienced one or more adverse event. One 
explanation for this result is that AA/B+ patients exposed to extended treatment leading to 
completion were subject to more severe physiologic stressors that resulted in a larger proportion 
of adverse events. It is likely the case, however, that adverse events also inform whether 
treatment is completed. In the latter situation, adverse events act not only to moderate the 
association between treatment completion and mortality, but also confound the association 
between treatment completion and mortality. 
Outside of the current investigation using the SEER-Medicare database, there are 
opportunities to conduct similar studies using a variety of analytical techniques in additional 
databases. In their investigation into the association between SCT and chronic kidney disease, 
Naik et al. (2014) pooled data across five large, prospective, US population-based cohorts 
(ARIC, JHS, CARDIA, MESA, WHI)ix, resulting in more than 15,000 AA/B individuals overall 
and 1,248 individuals with SCT (prevalence ranged from 6.3% to 9.3% among study cohorts).38 
Identification of SCT was ascertained through custom genotyping, exome sequencing, and 
imputation. While it is not possible to obtain genotyping data (‘gold standard’) for the SEER-
                                                 
ix ARIC: Atherosclerosis Risk in Communities Study; JHS: Jackson Heart Study; CARDIA: Coronary Artery Risk 
Development in Young Adults; MESA: Multi-Ethnic Study of Atherosclerosis; WHI: Women’s Health Initiative 
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Medicare cohort, we are currently investigating natural-language processing as a tool to abstract 
hemoglobinopathy status from clinical notes that would appear in an electronic medical record 
(EHR). While clinical notes are not as sensitive as genomic profiling data for determining SCT 
or other hemoglobinopathy status, they are more likely to be available in clinical settings for a 
larger proportion of the population overall compared to genotype data, and they are more likely 
to produce more accurate estimates of hemoglobinopathy prevalence compared to medical 
claims. Although universal newborn screening for hemoglobinopathies has only been in effect in 
the US since 2006, an increasing proportion of the population are becoming aware of their status. 
It will be of great importance for clinical health providers to ethically ascertain 
hemoglobinopathy status from patients to ensure this information is available in EMRs. 
In addition to having genotype data available for identifying SCT status, Naik et al. 
utilized pooled data across research cohorts. Upon receiving approval from both the NCI and 
Mayo Clinic, we will have the ability to pool data in a similar manner in order to increase the 
overall power of future investigations. In addition to SEER-Medicare and Mayo Clinic 
databases, we are also exploring the ability to link to other prospective cohorts or EMRs with 
tumor registry data. The WHI was utilized by Naik et al. to analyze the association between SCT 
and chronic kidney disease; we have proposed to use the WHI data in a similar manner to assess 
cancer outcomes.  
The Mayo Clinic database signifies two additional important future directions for 
investigating the relationship between hemoglobinopathies and cancer related adverse events. 
First, since the Mayo Clinic data comes from a tumor registry linked to an EMR and does not 
rely solely on claims for identification of hemoglobinopathies, analysis will not be limited to 
patients age ≥65. Second, the Mayo Clinic data contains data on other cancer sites in addition to 
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breast and prostate cancer. The SEER-Medicare database has this information available as well, 
but each cancer site needs to be requested separately and comes with an additional fee. While 
breast and prostate cancer represent excellent exemplar cancer sites due to their high prevalence 
in the population and the large outcome disparities observed between AA/B and NHW patients, 
there is evidence to suggest other solid tumors may be more sensitive to the adverse effects of 
hypoxia (i.e. head and neck cancer, cervical cancer). In addition, outcome disparities by race are 
not limited to breast and prostate cancer—disparities are documented across cancer sites 
including cancer of the colorectum, stomach, lung and bronchus, ovary, cervix, and uterine 
corpus.1  
  
4.5 Translational Implications 
Despite overall improvements in cancer-specific mortality rates since the 1990s in all 
groups, largely attributed to the introduction of improved cancer therapies and screening, racial 
disparities in outcomes persist between AA/B and NHW populations.1 While SCT has been 
historically considered a benign condition not associated with decreased life expectancy, a 
growing number of clinical complications have been found to be associated with SCT. Our study 
adds adverse cancer outcomes to the list of complications associated with SCT and other 
inherited hemoglobinopathies known to have a higher prevalence in AA/B populations. At 
present, hemoglobinopathies are not established as a clinically relevant prognostic indicator 
among patients with cancer, and therefore providers have no reason to obtain information from 
patients regarding their status. From a translational perspective, it will be important for providers 
to communicate with patients regarding the potential risks and treatment considerations 
associated with carrier status. Despite universal newborn screening in the US, survey estimates 
suggest that only 16% of the adult population with SCT is aware of their status.115 This fact is 
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reflected in the prevalence estimates of hemoglobinopathies in our study cohort. Assuming an 
8% prevalence of SCT, only 10% of AA/B patients expected to have SCT had claims and were 
therefore likely aware of their status (7% for prostate cancer patients and 13.9% for breast cancer 
patients). 
In the preliminary CTR chart review, breast cancer patients were informed of their SCT 
carrier status after a complication occurred. In the SEER-Medicare study cohort, approximately 
60% of patients had a claim for a hemoglobinopathy after diagnosis. Claims are an imperfect 
proxy for the timing of when a patient learns about her/his hemoglobinopathy status, but it 
suggests and perhaps confirms that a majority of cancer patients are informed of their 
hemoglobinopathy status after cancer diagnosis. Based on this information, health care providers 
may be responsible for taking initiative to communicate with patients about whether they have a 
hemoglobinopathy, and potentially to screen individuals who have immigrated from or have 
ancestry from an area with a high prevalence of SCT or thalassemia. Overall, the timing of a 
hemoglobinopathy claim did not appear to be associated with treatment completion or vital status 
in the SEER-Medicare cohort.  
 Results from this study prompt a number of translational science research questions. 
First, a deeper understanding of the potential histologic differences in the tumor 
microenvironment between patients with hemoglobinopathies and those without will elucidate 
associations between hypoxia and intratumoral sickling. In a case report documenting 
intratumoral sickling in a patient with cervical cancer and sickle cell trait, Milosevic et al. (2001) 
obtained a punch biopsy of the tumor which confirmed moderately differentiated invasive 
squamous cell carcinoma, with extensive RBC sickling and severe hypoxia.48 The amplification 
cycle of tumor hypoxia and RBC sickling leading to enhanced tumor growth and reduced 
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sensitivity to radiation and chemotherapy has important clinical implications regarding modified 
treatment and monitoring plans. Results from our observational study provide indirect evidence 
to suggest that hemoglobinopathies influence the occurrence of adverse events and patient 
mortality, but further histologic study of cancers in individuals with SCT is warranted. In 
addition to SCT, it is worthwhile to consider additional hemoglobinopathies as well to determine 
if a similar mode of action appears across a range of hemoglobinopathies.  
 Overall, results from this retrospective observational research study represent the first 
formal population-based study of SCT and other hemoglobinopathies as an adverse prognostic 
factor in older adults with cancer. In his 2015 State of the Union Address, President Barack 
Obama announced a new Precision Medicine Initiative, “…to bring us closer to curing diseases 
like cancer and diabetes – and to give all of us access to the personalized information we need to 
keep ourselves and our families healthier”.116 The concept of precision medicine focuses 
specifically on cancer, aiming to gain insight into inherited genetic variations that drive disease 
prevention, treatment, prognosis, and outcomes on a population scale.116 The present 
investigation of the prognostic influence of inherited hemoglobin variants and their subsequent 
contribution to racial disparities in cancer outcomes falls perfectly into the framework of 
precision medicine. This framework also provides a roadmap to future studies measuring the 
pharmacogenomics for SCT carriers with cancer, allowing treatment dose, intensity, and overall 
plan to be tailored for each individual patient, thereby giving this patient population the greatest 
chance to reduce morbidity and improve survival outcomes.
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Tables 
Table 1.1. CTR Preliminary chart review: Demographic and clinicopathological 
characteristics by study group 
 
 
Characteristics
AA/B SCT +
(n = 12)
NHW SCT +
(n = 2)
AA/B SCT -
(n = 40)
NHW SCT -
(n = 40)
Median follow-up, months (IQR) 46 (30 - 115) 62 (53 - 71) 88 (44 - 138) 99 (60 - 133)
Age at diagnosis, mean (SD) 55.5 (12.9) 46.0 (6.4) 53.5   (9.8) 54.6 (11.3)
Stage
0 1 (8.3) 1 (50.0) 4 (10.0)   1    (2.5)
I 5 (41.7) 1 (50.0) 10 (25.0) 13 (32.5)
II 3 (25.0) -- 20 (50.0) 16 (40.0)
III 3 (25.0) --  6 (15.0)   7 (17.5)
IV -- -- --  2   (5.0)
BMI, mean (SD) 33.5 (7.1) 25.2 (0.0) 32.8 (10.0) 29.4   (8.3)
Vital status
Alive 8 (66.7) 1 (50.0) 27 (67.5) 34 (85.0)
Dead 4 (33.3) 1 (50.0) 13 (32.5) 6 (15.0)
Smoking history
Never 8 (66.7) 0   (0.0) 22 (55.0) 17 (42.5)
Former 3 (25.0) 0   (0.0) 12 (30.0) 16 (40.0)
Current 1   (8.3) 1 (50.0) 4 (10.0) 5 (12.5)
NOS 0   (0.0) 1 (50.0) 2   (5.0) 2   (5.0)
Number of comorbid conditions
(CCI
a
 Score)
0 1   (8.3) 0   (0.0) 2   (5.0) 2   (5.0)
1 3 (25.0) 0   (0.0) 6 (15.0) 7 (17.5)
2+ 6 (50.0) 1 (50.0) 17 (42.5) 9 (22.5)
missing 3 (25.0) 1 (50.0) 15 (37.5) 22 (55.0)
Family history of cancer 3 (25.0) 0   (0.0) 19 (47.5) 11 (27.5)
a 
Charlson Cormorbidity Index
Clinical Phenotype
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Table 1.2. Breast cancer patients who experienced adverse events during or after cancer 
therapy 
 
 
Surgery 
n (%)
Radiation
n (%)
Chemotherapy
n (%)
AA/B SCT+ (n=12)
No. received 12 (100) 6 (50.0) 8 (66.7)
Any AE 7 (58.3) 5 (83.3) 6 (75.0)
Potential sickling-related AE 1   (8.3) 0   (0.0) 4 (50.0)
AA/B SCT- (n=40)
No. received 38 (95.0) 29 (72.5) 29 (72.5)
Any AE 12 (31.6) 11 (37.9) 17 (58.6)
Potential sickling-related AE 2   (5.3) 0   (0.0) 3 (10.3)
NHW SCT- (n=40)
No. received 38 (95.0) 25 (62.5) 22 (55.0)
Any AE 6 (15.8) 3 (12.0) 7 (31.8)
Potential sickling-related AE 0   (0.0) 0   (0.0) 1   (4.5)
AE: adverse event; SCT: sickle-cell trait
a
Patients who received more than one modality are counted in each category
Treatment modality
a
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Table 2.1. SEER-Medicare data files83 
 
File Name Years 
Included 
File Summary Diagnosis/Procedure 
Codes 
Patient entitlement 
and diagnosis 
summary file 
(PEDSF) 
2007-2013 • SEER data 
• Medicare HMO and 
entitlement (month/year) 
SEER coding 
Summarized 
denominator file for 
non-cancer cases 
(SUMDENOM) 
2006-2014 • 5% random sample of 
Medicare beneficiaries 
residing in SEER areas 
without a diagnosis of cancer 
• Medicare HMO and 
entitlement (month/year) 
None 
Medicare analysis 
and procedure file 
(MEDPAR) 
2006-2014 • Part A coverage 
• 100% Medicare 
hospitalizations with one 
record per hospitalization 
ICD-9 diagnosis and 
HCPCS† procedures 
Outpatient 2006-2014 • Part B coverage 
• 100% Medicare outpatient 
claims with multiple 
procedures for the same date 
of service 
HCPCS and revenue 
center procedures 
Carrier -
Physician/supplier 
(NCH) 
2006-2014 • Part B coverage 
• 100% Physician/Provider 
claims for single date of 
service 
ICD-9 diagnosis and 
HCPCS procedures 
Hospice 2006-2014 • Part B coverage 
• 100% of claims for one or 
more dates 
ICD-9 diagnosis 
codes 
Home Health 
Agency (HHA) 
2006-2014 • Part A/Part B coverage 
• 100% of claims for one or 
more dates 
ICD-9 diagnosis 
codes 
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File Name Years 
Included 
File Summary Diagnosis/Procedure 
Codes 
Durable Medical 
Equipment (DME) 
2006-2014 • Part B coverage 
• 100% of claims for one or 
more dates 
ICD-9 diagnosis and 
HCPCS codes 
† HCPCS: Health Care Common Procedure Classification System 
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Table 2.2. Hemoglobinopathy Codes used to Identify Diagnosed Patients  
 
Disorder/Variant ICD-9 
Thalassemia 282.4 
Sickle-cell beta thalassemia 
282.41 
282.42 
Alpha thalassemia 282.43 
Beta thalassemia 282.44 
Delta-beta thalassemia 282.45 
Beta thalassemia trait 282.46 
Hemoglobin E-beta thalassemia 282.47 
Other thalassemia variants 282.49 
Sickle-cell trait 282.5 
Sickle-cell disease 282.6 
Other sickle-cell variants 
282.61 
282.62 
282.63 
282.64 
Sickle-cell anemia without crisis 282.68 
Sickle-cell anemia with crisis 282.69 
Other hemoglobinopathies 282.7 
Hemoglobin C disease 282.7 
Hemoglobin E disease 282.7 
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Table 3.1. Demographic and clinicopathological characteristics by study group  
 
n % n % n % n %
Median Follow-up time 
(months), IQR
56 35 - 80 52 33 - 78 53 32 - 77 57 35 - 80 <.001
Tumor site
Breast (female only) 75,633 46.53 187 50.40 6,732 38.91 68,714 47.43 <.001
Prostate 86,904 53.47 184 49.60 10,571 61.09 76,149 52.57
Age
66-74 89,954 55.34 233 62.80 10,554 61.00 79,167 54.65 <.001
75 to 84 55,910 34.40 106 28.57 5,335 30.83 50,469 34.84
≥85 16,673 10.26 32 8.63 1,414 8.17 15,227 10.51
Year of diagnosis
2007 26,794 16.48 64 17.25 2,723 15.74 24,007 16.57
2008 25,163 15.48 47 12.67 2,650 15.32 22,466 15.51
2009 23,852 14.67 57 15.36 2,591 14.97 21,204 14.64
2010 23,199 14.27 45 12.13 2,509 14.50 20,645 14.25
2011 23,285 14.33 70 18.87 2,480 14.33 20,735 14.31
2012 20,379 12.54 39 10.51 2,269 13.11 18,071 12.47
2013 19,865 12.22 49 13.21 2,081 12.03 17,735 12.24
SEER Registry Area
Northeast 34,750 21.38 72 19.41 3,471 20.06 31,207 21.54
Midwest 20,769 12.78 76 20.49 2,599 15.02 18,094 12.49
South 45,492 27.99 146 39.35 8,007 46.28 37,339 25.78
West 61,526 37.85 77 20.75 3,226 18.64 58,223 40.19
Urban/Rural Residence
Metro 133,473 82.12 329 88.68 15,183 87.75 117,961 81.43
Nonmetro 29,064 17.88 42 11.32 2,120 12.25 26,902 18.57
Median Household Income ($), 
IQR
59,701 43.1 - 82.4 39,289 27.2 - 54.2 40,415 28.5 - 56.7 61,701 45.5 - 84.6 <.001
Median %  Without HS 
Education, IQR
9.95 5.37 - 18.17 20.25 12.15 - 27.15   18.28 11.06 - 26.16 8.97 4.92 - 15.63 <.001
.017
<.001
<.001
Total
(n = 162,537)
AA/B+
(n = 371)
AA/B-
(n = 17,303)
NHW-
(n = 144,863) p-value
c
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Table 3.1 (con’t). 
 
 
 
 
 
n % n % n % n %
Marital Status
Married 88,895 54.69 150 40.43 6,903 39.89 81,842 56.50
Not married 57,235 35.21 180 48.52 8,246 47.66 48,629 33.57
Other 16,407 10.09 41 11.05 1,974 11.41 14,392 9.93
Charlson Comorbidity Score
0 71,354 43.90 85 22.91 6,467 37.38 71,354 49.26
1-2 55,175 33.95 150 40.43 6,861 39.65 55,175 38.09
≥3 18,334 11.28 136 36.66 3,975 22.97 18,334 12.66
AJCC Stage
0 11,811 7.27 34 9.16 1,157 6.69 10,620 7.33
I 31,473 19.36 67 18.06 2,125 12.28 29,281 20.21
II 87,111 53.59 190 51.21 10,242 59.19 76,679 52.93
III 10,735 6.60 21 5.66 1,073 6.20 9,641 6.66
IV 10,903 6.71 37 9.97 1,507 8.71 9,359 6.46
Unknown 10,504 6.46 22 5.93 1,199 6.93 9,283 6.41
Number of positive lymph 
0 49,746 30.61 108 29.11 3,834 22.16 45,804 31.62
1-3 9,723 5.98 19 5.12 991 5.73 8,713 6.01
>4 4,184 2.57 13 3.50 475 2.75 3,696 2.55
No nodes examined 94,427 58.10 215 57.95 11,445 66.14 82,767 57.13
Unknown 4,457 2.74 16 4.31 558 3.22 3,883 2.68
<.001
<.001
<.001
<.001
Total
(n = 162,537)
AA/B+
(n = 371)
AA/B-
(n = 17,303)
NHW-
(n = 144,863) p-value
c
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Table 3.1 (con’t). 
 
 
 
n % n % n % n %
Tumor characteristics - 
breast
Tumor Size (cm)a
0-2 41,715 55.15 91 48.66 3,060 45.45 38,564 56.12
2.1-3 22,274 29.45 64 34.22 2,226 33.07 19,984 29.08
≥4 4,510 5.96 17 9.09 639 9.49 3,854 5.61
Unknown 7,134 9.43 15 8.02 807 11.99 6,312 9.19
Histology
a
Ductal 61,831 81.75 160 85.56 5,526 82.09 56,145 81.71
Lobular 7,931 10.49 11 5.88 584 8.67 7,336 10.68
Other 5,871 7.76 16 8.56 622 9.24 5,233 7.62
Grade
a
Well differentiated (1) 16,800 22.21 30 16.04 1,072 15.92 15,698 22.85
Moderately differentiated (2) 30,735 40.64 62 33.16 2,522 37.46 28,151 40.97
Poorly differentiated (3) 19,171 25.35 65 34.76 2,133 31.68 16,973 24.70
Undifferentiated (4) 933 1.23 n/a
d
n/a 72 1.07 861 1.25
Unknown 7,994 10.57 n/a n/a 933 13.86 7,031 10.23
Estrogen Receptor Status
a
Positive 59,251 78.34 130 69.52 4,749 70.54 54,372 79.13
Negative 10,077 13.32 40 21.39 1,328 19.73 8,709 12.67
Unknown 6,305 8.34 17 9.09 655 9.73 5,633 8.20
Progesterone Receptor Status
a
Positive 50,537 66.82 113 60.43 3,978 59.09 46,446 67.59
Negative 18,009 23.81 56 29.95 2,045 30.38 15,908 23.15
Unknown 7,087 9.37 18 9.63 709 10.53 6,360 9.26
<.001
<.001
<.001
<.001
<.001
Total
(n = 162,537)
AA/B+
(n = 371)
AA/B-
(n = 17,303)
NHW-
(n = 144,863) p-value
c
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Table 3.1 (con’t). 
 
 
 
 
 
 
 
 
 
 
n % n % n % n %
Tumor Characteristics - 
prostate
Gleason Score
b
Well-differentiated, 2-4 845 0.97 n/a n/a 110 1.04 734 0.96
Moderately-differentiated, 5-7 48,744 56.09 103 55.98 5,770 54.58 42,871 56.30
Poorly-differentiated, 8-10 31,990 36.81 63 34.24 3,959 37.45 27,968 36.73
Unknown 5,325 6.13 n/a n/a 732 6.92 4,576 6.01
<.001
Notes :
a
breast cancer only
b
prostate cancer only
c
Chi-square test for categorical data and Kruskal-Wallis one-way ANOVA for continuous variables
d
values n/a suppressed due to cell size n<11
Total
(n = 162,537)
AA/B+
(n = 371)
AA/B-
(n = 17,303)
NHW-
(n = 144,863) p-value
c
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Table 3.2. Distribution of selected comorbidities in the Charlson Comorbidity Index (CCI) by study group 
 
 
 
 
 
 
Selected comorbidities (yes) n % n % n %
Myocardial infarction* 11 2.96 252 1.46 1,767 1.22 <.001 .018
Congestive heart failure* 77 20.75 2,181 12.60 11,547 7.97 <.001 <.001
Peripheral vascular disease 42 11.32 1,934 11.18 10,880 7.51 <.001 .930
Cerebrovascular disease* 67 18.06 2,375 13.73 17,041 11.76 <.001 .017
COPD*
a
88 23.72 3,099 17.91 24,467 16.89 <.001 .004
Dementia 10 2.70 482 2.79 2,384 1.65 <.001 .917
Paralysis n/a
d
n/a 196 1.13 643 0.44 <.001 .177
Diabetes* 206 55.53 6,716 38.81 35,231 24.32 <.001 <.001
Diabetes with sequelae* 82 22.10 2,217 12.81 8,785 6.06 <.001 <.001
Chronic renal failure* 94 25.34 2,437 14.08 10,182 7.03 <.001 <.001
Moderate-severe liver disease n/a n/a 43 0.25 231 0.16 .019 .336
Ulcers* 13 3.50 308 1.78 1,672 1.15 <.001 .014
Connective tissue disorders* 23 6.20 561 3.24 4,364 3.01 <.001 .002
AIDS n/a n/a 60 0.35 74 0.05 <.001 .140
Notes:
*Statistically significant difference between AA/B+ vs. AA/B-
a
Chronic obstructive pulmonary disease
b
Chi-square test
d
values n/a suppressed due to cell size n<11
AA/B+
(n = 371)
AA/B-
(n = 17,303)
NHW-
(n = 144,863) p-value
b AA/B+ vs. AA/B-
p-value*
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Table 3.3. Breast cancer treatment receipt characteristics by study group 
 
 
 
Receipt of Breast Cancer 
Treatment
a
n % n % n % n %
Surgery
Breast-conserving surgery (BCS) 42,545 56.25 89 47.59 3,084 45.81 39,372 57.30
Mastectomy 22,617 29.90 63 33.69 2,196 32.62 20,358 29.63
No initial surgery 10,471 13.84 35 18.72 1,452 21.57 8,984 13.07
Radiation therapy (RT)
Yes 37,300 49.32 83 44.39 2,777 41.25 34,440 50.12
No 38,333 50.68 104 55.61 3,955 58.75 34,274 49.88
Receipt of chemotherapy
Yes 19,849 26.24 58 31.02 2,017 29.96 17,774 25.87
No 55,784 73.76 129 68.98 4,715 70.04 50,940 74.13
Combined therapy (yes)
BCS+RT 31,287 41.37 63 33.69 2,194 32.59 29,030 42.25 <.001
Mastectomy+RT 4,203 5.56 12 6.42 384 5.70 3,807 5.54 .749
BCS+RT+Chemotherapy 6,915 9.14 15 8.02 533 7.92 6,367 9.27 .001
Mastectomy+RT+Chemotherapy 2,392 3.16 n/a n/a 208 3.09 2,180 3.17 .678
a
Treatment received within 9 months of diagnosis
b
Chi-square test
<.001
<.001
<.001
Total
(n = 75,633)
AA/B+
(n = 187)
AA/B-
(n = 6,732)
NHW-
(n = 68,714)
p-value
b
 83 
 
 
 
Table 3.4. Prostate cancer treatment receipt characteristics by study group 
 
Receipt of Prostate Cancer Treatment n % n % n % n %
Initial curative therapy
a
Yes 61,760 71.07 129 70.11 7,136 67.51 54,495 71.56
No 25,144 28.93 55 29.89 3,435 32.49 21,654 28.44
Prostatectomy
b
Yes 16,561 19.06 25 13.59 1,291 12.21 15,245 20.02
No 70,343 80.94 159 86.41 9,280 87.79 60,904 79.98
Radiation Therapy (RT)
b
Yes 39,638 45.61 81 44.02 4,872 46.09 34,685 45.55
No 47,266 54.39 103 55.98 5,699 53.91 41,464 54.45
Androgen Deprivation Therapy (ADT)
b
Yes 29,699 34.17 73 39.67 3,804 35.99 25,822 33.91
No 57,205 65.83 111 60.33 6,767 64.01 50,327 66.09
Chemotherapy
b
Yes 30,904 35.56 79 42.93 3,926 37.14 26,899 35.32
No 56,000 64.44 105 57.07 6,645 62.86 49,250 64.68
<.001
<.001
.528
<.001
<.001
a
Receipt of surgery, radiation, or ADT within 180 days of diagnosis
bTreatment received within 12 months of diagnosis
c
Chi-square test
Total
(n = 86,904)
AA/B+
(n = 184)
AA/B-
(n =  10,571)
NHW-
(n = 76,149) p-value
c
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Table 3.5. Treatment completion for breast cancer patients by stage and study group 
 
 
n % n % n % n %
Stage
I    (n= 31,343) 17,399 55.51 34 50.75 1,081 51.21 16,284 55.83 <.001
II   (n= 18,774) 7,936 42.27 11 22.92 645 34.81 7,280 43.15 <.001
III  (n= 3,263) 601 18.42 n/a n/a 45 6.62 556 10.85 .001
IV (n= 4,145) 635 15.32 n/a n/a 70 13.01 563 15.67 .278
Total 37,077 52.16 79 44.38 2,854 45.40 34,144 52.84 <.001
a
Number of breast cancer patients with sufficient stage at diagnosis information to be included in analysis of treatment completion
c
Chi-square test
Completion of Breast Cancer 
Treatment (yes)
a
Total
a
(n = 71,078)
AA/B+
(n = 178)
AA/B-
(n = 6,287)
NHW-
(n = 64,613) p-value
c
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Table 3.6. Treatment completion for prostate cancer patients by stage and study group 
 
 
 
n % n % n % n %
Stage
I   (n= 52,519) 49,797 94.82 104 96.30 6,309 92.08 43,384 95.23 <.001
II  (n= 25,676) 10,906 42.48 20 37.04 884 33.47 10,002 43.52 <.001
III (n= 2,141) 1,344 62.77 n/a n/a 85 43.37 1,258 64.75 <.001
IV (n= 989) 694 0.70 n/a n/a 79 59.40 612 71.92 .012
Total 62,741 77.15 128 75.74 7,357 74.90 55,256 77.46 <.001
p-value
c
a
Number of prostate patients with sufficient stage at diagnosis information to be included in analysis of treatment completion
c
Chi-square test
Completion of Prostate Cancer 
Treatment (yes)
a
Total
a
(n = 81,325)
AA/B+
(n = 169)
AA/B-
(n = 9,822)
NHW-
(n = 71,334)
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Table 3.7. Risk of incomplete treatment by study group and cancer site 
 
Study group
Unadjusted 
RR
(95% CI) p-value
Adjusted 
RR
a
(95% CI) p-value
PS weighted 
RR
b
(95% CI) p-value
All patients
NHW- 1.00 -- -- 1.00 -- -- 1.00 -- --
AA/B- 1.21 1.19 - 1.23 <.001 1.11 1.09 - 1.13 <.001 1.09 1.06 - 1.13 <.001
AA/B+ 1.13 1.00 - 1.27 .049 1.05 0.94 - 1.17 .393 1.03 0.89 - 1.18 .737
Breast cancer
NHW- 1.00 -- -- 1.00 -- -- 1.00 -- --
AA/B- 1.16 1.13 - 1.20 <.001 1.05 1.03 - 1.08 <.001 1.01 0.96 - 1.05 .816
AA/B+ 1.19 1.01 - 1.40 .038 1.10 0.96 - 1.27 .159 1.00 0.82 - 1.21 .974
Prostate cancer
NHW- 1.00 -- -- 1.00 -- -- 1.00 -- --
AA/B- 1.22 1.19 - 1.25 <.001 1.17 1.14 - 1.20 <.001 1.17 1.12 - 1.22 <.001
AA/B+ 1.07 0.90 - 1.27 .451 1.04 0.89 - 1.21 .627 1.14 0.84 - 1.27 .737
Note : Relative Risk (RR) estimated using modified Poisson regression with robust error variance
a
Adjusted for age, year of diagnosis, SEER region, metro residence, maritial status, income, CCI score, stage, number of positive lymph nodes, adverse events after surgery or 
chemotherapy; Prostate cancer model adjusted for age, year of diagnosis, SEER region, metro residence, maritial status, income, CCI score, stage, number of positive lymph 
nodes, adverse events after surgery or ADT
b
Further adjusted for adverse events 30 days after surgery or 180 days after chemotherapy
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Table 3.8. Adverse events by study group 
 
n % n % n % n %
TOTAL 135,036 309 13,563 121,164
Number of adverse events
0 45,557 33.74 46 14.89 3,750 27.65 41,761 34.47
1 45,972 34.04 93 30.10 4,657 34.34 41,222 34.02
2 26,008 19.26 84 27.18 3,076 22.68 22,848 18.86
≥3 17,499 12.96 86 27.83 2,080 15.34 15,333 12.65
Adverse event within 90 days of 
surgery
b
Yes 9,969 12.19 28 15.64 946 14.37 8,995 11.99
No 71,828 87.81 151 84.36 5,637 85.63 66,040 88.01
Adverse event within 180 days of 
chemotherapy or ADT
c
Yes 10,171 19.73 34 24.64 1,373 22.49 8,764 19.34
No 41,375 80.27 104 75.36 4,731 77.51 36,540 80.66
Adverse events known to be 
associated with hemoglobinopathies
d
Yes 15,402 11.41 69 22.33 1,708 12.59 13,625 11.25
No 119,634 88.59 240 77.67 11,855 87.41 107,539 88.75
Adverse events putatively 
associated with hemoglobinopathies
e
Yes 19,083 14.13 78 25.24 2,200 16.22 16,805 13.87
No 115,953 85.87 231 74.76 11,363 83.78 104,359 86.13
Adverse events associated with 
chemotherapy toxicity
f
Yes 34,467 25.52 126 40.78 4,010 29.57 30,331 25.03
No 100,569 74.48 183 59.22 9,553 70.43 90,833 74.97
Emergency room visit
Yes 64,165 47.52 176 56.96 7,116 52.47 56,873 46.94
No 70,871 52.48 133 43.04 6,447 47.53 64,291 53.06
a
n = 135,036 patients received treatment (any surgery, any radiation, any chemotherapy, ADT)
b
n = 81,797 patients received surgery
c
n = 51,546 patients received chemotherapy or ADT
d
Hematuria, renal papillary necrosis, acute chest syndrome, anemia, myocardial infarction, thrombocytopenia, hyposthenuria, deep vein thromboembolism, splenic 
infarction, rhabdommyolysis, hyphema, priapism, leg ulcers, cholelithiasis, stroke
e
Neutropenia, shortness of breath, pain, hemiplegia, renal toxicity, hepatic toxicity, hemolysis, organ failure, respiratory dysfunction/dyspnea
f
Infection, fever, mailaise, leukopenia, fracture, pulmonary, cardiac events, blood transfusion, hypercholesterolemia, nephritis, adverse events of antineoplastic and 
immunosuppressive drugs
<.001
Total
a
(n = 135,036)
<.001
<.001
<.001
<.001
<.001
AA/B+
(n = 309)
AA/B-
(n = 13,563)
NHW-
(n = 121,164) p-value
<.001
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Table 3.9. Risk of one or more adverse event requiring hospitalization or emergency room visits 
 
 
 
Study group
Unadjusted 
RR
(95% CI) p-value
Adjusted 
RR
a
(95% CI) p-value
PS weighted 
RR
(95% CI) p-value
All patients
NHW- 1.00 -- -- 1.00 -- -- 1.00 -- --
AA/B- 1.10 1.09 - 1.12 <.001 1.03 1.02 - 1.05 <.001 1.03 1.01 - 1.06 <.001
AA/B+ 1.30 1.24 - 1.36 <.001 1.16 1.11 - 1.22 <.001 1.23 1.15 - 1.31 <.001
AA/B+ vs. AA/B- 1.18 1.12 - 1.23 <.001 1.12 1.07 - 1.18 <.001 1.19 1.11 - 1.27 <.001
Breast cancer
NHW- 1.00 -- -- 1.00 -- -- 1.00 -- --
AA/B- 1.11 1.09 - 1.13 <.001 1.02 0.99 - 1.03 .061 1.02 0.99 - 1.05 0.12
AA/B+ 1.29 1.22 - 1.38 <.001 1.14 1.07 - 1.22 <.001 1.20 1.08 - 1.33 <.001
AA/B+ vs. AA/B- 1.16 1.09 - 1.24 <.001 1.12 1.05 - 1.20 <.001 1.17 1.06 - 1.30 .002
Prostate cancer
NHW- 1.00 -- -- 1.00 -- -- 1.00 -- --
AA/B- 1.10 1.08 - 1.12 <.001 1.05 1.04 - 1.07 <.001 1.04 1.01 - 1.07 <.001
AA/B+ 1.30 1.21 - 1.40 <.001 1.18 1.10 - 1.26 <.001 1.25 1.14 - 1.36 <.001
AA/B+ vs. AA/B- 1.19 1.10 - 1.27 <.001 1.12 1.04 - 1.20 .002 1.20 1.10 - 1.30 <.001
Note : Relative Risk (RR) estimated using modified Poisson regression with robust error variance
a
Adjusted for age, year of diagnosis, SEER region, metro residence, maritial status, income, education, CCI score, stage, 
number of positive lymph nodes
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Table 3.10. Risk of one or more adverse event requiring hospitalization or emergency room visit among patients who 
completed treatment 
 
Study group
Unadjusted 
RR
(95% CI) p-value
Adjusted 
RR
a
(95% CI) p-value
PS weighted 
RR
(95% CI) p-value
All patients
NHW- 1.00 -- -- 1.00 -- -- 1.00 -- --
AA/B- 1.11 1.09 - 1.13 <.001 1.03 1.01 - 1.05 .001 1.03 1.00 - 1.05 .041
AA/B+ 1.35 1.26 - 1.45 <.001 1.19 1.11 - 1.28 <.001 1.21 1.10 - 1.33 <.001
AA/B+ vs. AA/B- 1.21 1.13 - 1.30 <.001 1.16 1.08 - 1.24 <.001 1.17 1.07 - 1.29 <.001
Breast cancer
NHW- 1.00 -- -- 1.00 -- -- 1.00 -- --
AA/B- 1.10 1.08 - 1.13 <.001 1.01 0.98 - 1.04 .568 1.01 0.96 - 1.05 .721
AA/B+ 1.35 1.21 - 1.49 <.001 1.18 1.06 - 1.32 .002 1.18 0.98 - 1.42 .084
AA/B+ vs. AA/B- 1.22 1.10 - 1.35 <.001 1.17 1.05 - 1.31 .004 1.17 0.97 - 1.41 .098
Prostate cancer
NHW- 1.00 -- -- 1.00 -- -- 1.00 -- --
AA/B- 1.11 1.09 - 1.14 <.001 1.05 1.03 - 1.07 <.001 1.04 1.01 - 1.07 .020
AA/B+ 1.35 1.24 - 1.48 <.001 1.20 1.10 - 1.31 <.001 1.22 1.09 - 1.36 <.001
AA/B+ vs. AA/B- 1.22 1.11 - 1.34 <.001 1.14 1.04 - 1.25 .003 1.17 1.06 - 1.31 .003
Note : Relative Risk (RR) estimated using modified Poisson regression with robust error variance
a
Adjusted for age, year of diagnosis, SEER region, metro residence, maritial status, income, education, CCI score, stage, 
number of positive lymph nodes
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Table 3.11. Risk of one or more adverse event requiring hospitalization or emergency room visit among patients who did not 
complete treatment 
 
Study group
Unadjusted 
RR
(95% CI) p-value
Adjusted 
RR
a
(95% CI) p-value
PS weighted 
RR
(95% CI) p-value
All patients
NHW- 1.00 -- -- 1.00 -- -- 1.00 -- --
AA/B- 1.07 1.06 - 1.09 <.001 1.01 1.00 - 1.03 .159 1.00 0.96 - 1.02 .487
AA/B+ 1.24 1.16 - 1.32 <.001 1.12 1.05 - 1.20 .004 1.13 1.02 - 1.25 .009
AA/B+ vs. AA/B- 1.15 1.07 - 1.23 <.001 1.11 1.03 - 1.18 .004 1.14 1.02 - 1.29 .016
Breast cancer
NHW- 1.00 -- -- 1.00 -- -- 1.00 -- --
AA/B- 1.09 1.07 - 1.11 <.001 1.01 0.99 - 1.03 .192 1.01 0.97 - 1.04 .721
AA/B+ 1.20 1.11 - 1.30 <.001 1.09 1.00 - 1.19 .040 1.14 1.01 - 1.26 .018
AA/B+ vs. AA/B- 1.10 1.01 - 1.19 .025 1.08 0.99 - 1.18 .084 1.13 1.02 - 1.25 .024
Prostate cancer
NHW- 1.00 -- -- 1.00 -- -- 1.00 -- --
AA/B- 1.06 1.03 - 1.09 <.001 1.02 0.99 - 1.05 .123 0.96 0.91 - 1.01 .137
AA/B+ 1.31 1.17 - 1.47 <.001 1.18 1.06 - 1.31 .002 1.11 0.89 - 1.38 .348
AA/B+ vs. AA/B- 1.24 1.10 - 1.39 <.001 1.15 1.03 - 1.28 .009 1.15 0.93 - 1.44 .190
Note : Relative Risk (RR) estimated using modified Poisson regression with robust error variance
a
Adjusted for age, year of diagnosis, SEER region, metro residence, maritial status, income, education, CCI score, stage, 
number of positive lymph nodes
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Table 3.12. Survival characteristics by study group and cancer site. 
 
Outcome n % n % n %
Breast cancer
Survival, median (IQR), months 52 (33 - 78) 47 (29 - 72) 53 (33 - 77) <.001
Vital status
Alive 130 69.52 4,281 63.59 49,484 72.01
Dead 57 30.48 2,451 36.41 19,230 27.99
Cause of death
Breast cancer 17 29.82 886 36.02 5,447 28.33
Other/unknown 40 70.18 1,565 63.62 13,783 71.67
2-year survival, % (95% CI) 89.89 (84.43 - 93.51) 87.71 (86.88 - 88.50) 91.65 (91.44 - 91.86) <.001
5-year survival, % (95% CI) 75.85 (68.13 - 81.94) 69.04 (67.76 - 70.29) 77.01 (76.65 - 77.36) <.001
Prostate cancer
Survival, median (IQR), months 52 (34 - 77.5) 55 (34 - 79) 59 (38 - 82) <.001
Vital status
Alive 109 59.24 7,261 68.69 56,642 74.38
Dead 75 40.76 3,310 31.31 19,507 25.62
Cause of death
Prostate cancer 17 22.67 738 22.30 4,201 21.54
Other/unknown 58 77.33 2,572 77.70 15,306 78.46
2-year survival, % (95% CI) 87.43 (81.54 - 91.54) 90.06 (89.46 - 90.62) 92.74 (92.55 - 92.93) <.001
5-year survival, % (95% CI) 67.95 (59.78 - 74.81) 74.59 (73.66 - 75.49) 79.90 (79.56 - 80.21) <.001
<.001
<.001
<.001
AA/B+
(n = 371)
AA/B-
(n = 17,303)
NHW-
(n = 144,863)
<.001
p -value
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Figures 
Figure 1.1. Proportion of breast cancer patients experiencing any complications/adverse events or potential sickling adverse 
event following treatment (surgery, radiation, or chemotherapy). 
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Figure 1.2. Conceptual Model 
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Figure 3.1. Distribution of comorbidities by study group 
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Figure 3.2. Distribution of Adverse Events (AEs) by category and study group 
 
 
*Pairwise comparisons between AA/B+ vs. AA/B- and NHW-, respectively, p <.001 
**Pairwise comparison between AA/B+ vs. AA/B-, p =.065; between AA/B+ vs. NHW-, p <.001
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Figure 3.3. Kaplan-Meier all-cause (top row), breast-cancer specific (middle row) and competing risk 
(bottom row) survival curves by study group for unadjusted (left panels) and propensity score weighted 
(right panels) breast cancer patients.  
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Figure 3.4. Kaplan-Meier all-cause (top row), prostate-cancer specific (middle row) and competing risk 
(bottom row) survival curves by study group for unadjusted (left panels) and propensity score weighted 
(right panels) prostate cancer patients.  
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Figure 3.5. Propensity score weighted hazard ratios (HRs) for death among breast and 
prostate cancer patients who failed to complete treatment by study group. 
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Figure 3.6. Propensity score weighted hazard ratios (HRs) for death among breast and 
prostate cancer patients who experienced one or more adverse event by study group.  
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Figure 4.1. Risk of one or more adverse event requiring hospitalization or emergency room 
visit by CCI Score. 
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Figure 4.2. Propensity score weighted hazard ratios (HRs) for death among breast and 
prostate cancer patients who experienced one or more adverse event by treatment 
completion status and study group.  
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Appendices 
Appendix A1. Cohort Selection Criteria – Breast Cancer 
246,524
Diagnosed with female breast 
cancer 2007-2013
246,524
iagnosed ith fe ale breast 
cancer 2007-2013
228,463
First or only primary tumor
228,463
First or only pri ary tu or
226,828
Histology consistent with 
epithelial origin
226,828
istology consistent ith 
epithelial origin
138,447
Age at diagnosis ≥66
138,447
ge at diagnosis ≥66
136,682
Known month of diagnosis, not 
diagnosed at death or autopsy
136,682
no n onth of diagnosis, not 
diagnosed at death or autopsy
85,227
Continuous AB/non-HMO 
coverage from 1 year before to 
1 year after diagnosis 
85,227
ontinuous /non-  
coverage fro  1 year before to 
1 year after diagnosis 
6,919
African American/Black
187
hemo+
n = 18,061 
(7.3%)
Exclude
69,216
Non-Hispanic White
6,732
hemo-
68,714
hemo-
n = 1,635 
(0.72%)
Exclude
n = 88,381
(39.0%)
Exclude
n = 1,765
(1.3%)
Exclude
n = 51,455
(37.7%)
Exclude
n = 296
(0.35%)
Exclude
84,931
Not diagnosed with other cancer 
in the year after diagnosis
84,931
ot diagnosed ith other cancer 
in the year after diagnosis
n = 8,796
(10.4%)
Exclude
n = 502
(0.66%)
Exclude
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Appendix A2. Cohort Selection Criteria – Prostate Cancer 
278,955
Diagnosed with prostate cancer 
2007-2013
278,955
iagnosed ith prostate cancer 
2007-2013
272,628
First or only primary tumor
272,628
First or only pri ary tu or
271,571
Histology consistent with 
adenocarcinoma
271,571
istology consistent ith 
adenocarcino a
175,408
Age at diagnosis ≥66
175,408
ge at diagnosis ≥66
171,427
Known month of diagnosis, not 
diagnosed at death or autopsy
171,427
no n onth of diagnosis, not 
diagnosed at death or autopsy
101,919
Continuous AB/non-HMO 
coverage from 1 year before to 
1 year after diagnosis 
101,919
ontinuous /non-  
coverage fro  1 year before to 
1 year after diagnosis 
10,755
African American/Black
184
hemo+
n = 6,327
(2.27%)
Exclude
76,642
Non-Hispanic White
10,571
hemo-
76,149
hemo-
n = 1,057 
(0.39%)
Exclude
n = 96,163 
(35.41%)
Exclude
n = 3,981
(2.27%)
Exclude
n = 69,508
(40.55%)
Exclude
n = 166
(0.16%)
Exclude
101,753
Not diagnosed with other cancer 
in the year after diagnosis
101,753
ot diagnosed ith other cancer 
in the year after diagnosis
n = 14,356
(14.11%)
Exclude
n = 493
(0.56%)
Exclude
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Appendix B1. Diagnosis and Treatment Codes – Breast cancer 
  Healthcare Common 
Procedure Coding System 
International Classification 
of Diseases, 9th revision 
Diagnosis     
Malignant neoplasm of 
female breast 
  174.0 - 174.9 
C500 – C509 (ICD-O-3) 
26000 (ICD-O-3 recode) 
Surgery     
Mastectomy 19180, 19182, 19200, 19220, 
19240, 19303, 19304, 19305, 
19306, 19307 
85.41, 85.42, 85.43, 85.44, 
85.45, 85.46, 85.47, 85.48 
Breast-conserving surgery 19110, 19120, 19125, 19126, 
19160, 19162, 19301, 19302 
85.20, 85.21, 85.22, 85.23, 
85.25 
Radiation   
 
External beam 
radiotherapy 
77402, 77403, 77404, 77406, 
77407, 77408, 77409, 77411, 
77412, 77413, 77414, 77416  
 V58.0, V67.1 
(administration) 
Intensity modulated 
radiotherapy 
77301, 77418, 0073T, 
G0174  
  
Brachytherapy 77761, 77762, 77763, 77776, 
77777, 77778, 77781, 77782, 
77783, 77784, 77799, 
0182T, 19296, 19297, 
19298, C9714, C9715 
  
Chemotherapy     
Agents & administration J9000-J9999, J0640, J8530, 
J8600, J8610, J8999, J8510, 
J8520, J8521, 96400-96549, 
Q0083-Q0085 
992.5, V58.1, V66.2, V67.2, 
V07.51 
(CEN: 0331, 0332, and 
0335) 
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Appendix B2. Diagnosis and Treatment Codes – Prostate cancer 
  Healthcare Common Procedure 
Coding System 
International 
Classification of Diseases, 
9th revision 
Diagnosis     
Malignant neoplasm of prostate   185.0 
C619 (ICD-O-3) 
28010 (ICD-O-3 recode) 
Surgery     
Prostatectomy 55801, 55810, 55812, 55815, 
55821, 55831, 55840, 55842, 
55845 
60.3, 60.4, 60.5, 60.62, 
60.69, 60.61 (local excision 
of lesion of prostate) 
Laparoscopic Radical 
Prostatectomy (robotic 
assistance) 
55866   
Radiation     
External beam radiotherapy 77402, 77403, 77404, 77406, 
77407, 77408, 77409, 77411, 
77412, 77413, 77414, 77416 
92.21 – 92.29 
Intensity-modulated radiation 
therapy 
77301, 77418, 0073T, G0174   
Image-guided radiation therapy 77421, 76950, 77014, 76370, 
C9722 
  
Brachytherapy 77326, 77328, 76873, 77776, 
77777, 77778, 77781, 77782, 
77783, 77784, 77799, G0256, 
G0261,  
  
Stereotactic Radiosurgery G0251, G0339, G0340, 0082T, 
77373 
  
Proton beam radiation therapy 77520, 77522, 77523, 77525   
Androgen Deprivation 
Therapy 
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  Healthcare Common Procedure 
Coding System 
International 
Classification of Diseases, 
9th revision 
orchiectomy 54520, 54521, 54522, 54535, 
54690, 54530 
62.4, 62.41, 62.42 
Hormone therapy 49510, 11980, J9202 (goserelin), 
J9217, J9218, J9219, J1950, 
C9430, (leuprolide), J3315 
(Triptorelin pamoate), C9216, 
S0165, (Abarelix), S0175 
(Flutamide), S9560 
 
Chemotherapy   
Agents & administration J9000-J9999, J0640, J8530, J8600, 
J8610, J8999, J8510, J8520, 
J8521, 96400-96549, Q0083-
Q0085 
992.5, V58.1, V66.2, 
V67.2, V07.51 
(CEN: 0331, 0332, and 
0335) 
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Appendix B3. Adverse Event Codes 
Adverse Event ICD-9 Code 
Anemia 281, 283, 284, 285 
Thrombocytopenia 287.4, 287.5 
Leukopenia 288.5 
Neutropenia 288.0 
Infections/fever 001.0–139.8, 780.6, 99.85 
Dehydration 276.5 
Nausea/vomiting/diarrhea/fatigue/headache 780.0, 780.52, 787.0, 787.91, 
564.5, 780.4, 784.0, 346 
Renal toxicity, renal failure (including chronic kidney 
disease) 
403.01, 403.11, 403.91, 404.02, 
404.03, 404.12, 404.13, 404.92, 
404.93, 588.0, V42.0, V45.1, 
583.6, 585, 586, V56, 584 
Deep vein thrombosis 444, 445, 451, 452, 453 
Pulmonary embolism 415 
Other pulmonary conditions  416-417, 518.0–518.89 
Emergency Room (ER) visit 99281 – 99285 (HCPCS) 
Adverse effect of systemic therapy E933.1 
Shortness of breath 786.05 
Severe chest pain 786.5 
Diffuse body aches, severe back pain, myalgia, 
artharalgia 
724.8, 729.10, 729.1, 719.4 
Hemiplegia 342 
Hepatic toxicity 573.9, 572.8, 570, 573.3 
Hemolysis 283 
Multiorgan failure 995.94 
Respiratory distress/dyspnea 518.81, 786.0 
Hypoxia 799.02 
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Adverse Event ICD-9 Code 
Mechanical ventilation 96.7 
Vaso-occlusive crisis 282.62 
Mucositis 528.0, 112.0, 101 
Hematuria 599.7 
Renal papillary necrosis 584.7 
Acute chest syndrome 517.3 
Hyposthenuria 593.89 
Splenic infarction 289.59 
Rhabdomyolysis 728.88 
Complicated hyphema 364.41 
Priapism 607.3 
Leg ulcers 707.25 
Gallstones/cholelithiasis, cholecystitis 574, 575 
Stroke 433-435 
Myocardial infarction 410.0-413.9 
Blood transfusion V58.2, 99.03, 99.04 
Cardiomyopathy/hypertension/heart failure 398.91, 401.0-4.05.9, 422.90, 
425.4, 425.9, 428 
Unspecified diseases of blood and blood-forming organs 289.9 
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Appendix C. Propensity Score Weighting and Balance Diagnostics 
########################################################################################################### 
library(twang) 
library(survey) 
 
#BREAST 
set.seed(1) 
bmnps <- mnps(hemo_cat ~ agecat + YRDX1 + mar_cat + seer_reg + stage + ln_pos + PCHRLSON + income_q +  
  hs_q + breast_grade + breast_hist + her2 + estrogen + progesterone + t_size, 
              data = breast1, 
              estimand = "ATE", 
              verbose = FALSE, 
              stop.method = c("es.mean","ks.mean"), 
              n.trees = 10000) 
 
plot(bmnps, plots=1, subset = "es.mean") 
plot(bmnps, plots=2, subset = "es.mean") 
plot(bmnps, plots=3, subset = "es.mean") 
 
#export summary table of balance diagnostics 
breastBT <- as.data.frame(bal.table(bmnps, es.cutoff = 0.1)) 
write.csv(breastBT, file = "breastBT.csv") 
 
#get weights and export to .csv 
breast1$w <- get.weights(bmnps,stop.method = "es.mean") 
write.csv(breast1, file = "bmnps.csv") 
 
########################################################################################################### 
 
#PROSTATE 
set.seed(1) 
pmnps <- mnps(hemo_cat ~ agecat + YRDX1 + mar_cat + seer_reg + stage + ln_pos + PCHRLSON + income_q +  
  hs_q + gleason + pros_stg, 
              data=prostate1, 
              estimand="ATE", 
              verbose = FALSE, 
              stop.method = c("es.mean","ks.mean"), 
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              n.trees = 10000) 
 
plot(pmnps, plots=1, subset = "es.mean") 
plot(pmnps, plots=2, subset = "es.mean") 
plot(pmnps, plots=3, subset = "es.mean") 
 
#export summary table of balance diagnostics 
prosBT <- as.data.frame(bal.table(pmnps, es.cutoff = 0.1)) 
write.csv(prosBT, file = "prostateBT.csv") 
 
#get weights and export to .csv 
prostate1$w <- get.weights(pmnps,stop.method = "es.mean") 
write.csv(prostate1, file = "pmnps.csv") 
########################################################################################################### 
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Figure C1. Summarized absolute standardized mean difference (ASMD) after 10,000 generalized boosted regression (GBM) 
model iterations for breast (left) and prostate (right) samples. 
 
    Breast         Prostate 
 
 112 
 
Figure C2. ASMD plots assessing maximum pairwise covariate balance after weighting by study group for breast (left) and 
prostate (right) samples. 
 Note: solid circle indicates statistically significant difference between unweighted and weighted ASMD. 
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Figure C3. Box plots of estimated propensity score overlap by study group for breast (left) and prostate (right) samples. 
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Table C1a. Maximum ASMD and minimum p-values remained >.10 across all pairwise 
comparisons for each covariate after weighting, breast cancer sample. 
 
Group 1 Group 2 variable mean1 mean2 pop.sd std.eff.sz p stop.method 
AA/B+ AA/B- agecat:1 0.595 0.505 0.5 0.181 0.100 es.mean 
AA/B+ AA/B- agecat:3 0.081 0.129 0.34 0.143 0.100 es.mean 
AA/B+ AA/B- YRDX1:2010 0.104 0.14 0.347 0.104 0.718 es.mean 
AA/B+ AA/B- YRDX1:2013 0.19 0.14 0.346 0.142 0.718 es.mean 
AA/B+ AA/B- mar_cat:1 0.29 0.343 0.477 0.11 0.297 es.mean 
AA/B+ AA/B- mar_cat:2 0.665 0.601 0.491 0.13 0.297 es.mean 
AA/B+ AA/B- seer_reg:4 0.228 0.294 0.459 0.143 0.456 es.mean 
AA/B+ AA/B- income_q:1 0.444 0.34 0.471 0.221 0.391 es.mean 
AA/B+ AA/B- hs_q:1 0.083 0.127 0.344 0.129 NA es.mean 
AA/B+ AA/B- hs_q:5 0.39 0.305 0.455 0.188 NA es.mean 
AA/B+ AA/B- hs_q:6 0 0 0 NA NA es.mean 
AA/B+ AA/B- breast_grade:4 0 0.011 0.107 0.102 0.423 es.mean 
AA/B+ AA/B- her2:1 0.019 0.055 0.224 0.164 0.056 es.mean 
AA/B+ NHW- agecat:1 0.595 0.504 0.5 0.182 0.090 es.mean 
AA/B+ NHW- agecat:3 0.081 0.132 0.34 0.15 0.090 es.mean 
AA/B+ NHW- YRDX1:2010 0.104 0.14 0.347 0.105 0.696 es.mean 
AA/B+ NHW- YRDX1:2013 0.19 0.136 0.346 0.154 0.696 es.mean 
AA/B+ NHW- mar_cat:1 0.29 0.354 0.477 0.134 0.201 es.mean 
AA/B+ NHW- mar_cat:2 0.665 0.591 0.491 0.151 0.201 es.mean 
AA/B+ NHW- seer_reg:4 0.228 0.309 0.459 0.177 0.275 es.mean 
AA/B+ NHW- income_q:1 0.444 0.317 0.471 0.27 0.185 es.mean 
AA/B+ NHW- income_q:5 0.092 0.137 0.341 0.132 0.185 es.mean 
AA/B+ NHW- hs_q:1 0.083 0.139 0.344 0.165 NA es.mean 
AA/B+ NHW- hs_q:5 0.39 0.288 0.455 0.224 NA es.mean 
AA/B+ NHW- hs_q:6 0 0 0 NA NA es.mean 
AA/B+ NHW- breast_grade:4 0 0.012 0.107 0.109 0.368 es.mean 
AA/B+ NHW- her2:1 0.019 0.053 0.224 0.155 0.067 es.mean 
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Table C1b. Maximum ASMD and minimum p-values remained >.10 across all pairwise 
comparisons for each covariate after weighting, prostate cancer sample. 
 
Group 1 Group 2 variable mean1 mean2 pop.sd std.eff.sz p stop.method 
AA/B+ AA/B- seer_reg:3 0.438 0.385 0.485 0.108 0.405 es.mean 
AA/B+ AA/B- seer_reg:4 0.208 0.268 0.445 0.134 0.405 es.mean 
AA/B+ AA/B- stage:0 0 0 0 NA NA es.mean 
AA/B+ AA/B- stage:99 0.048 0.078 0.269 0.109 NA es.mean 
AA/B+ AA/B- hs_q:1 0.083 0.123 0.334 0.12 0.693 es.mean 
AA/B+ NHW- seer_reg:3 0.438 0.385 0.485 0.109 0.311 es.mean 
AA/B+ NHW- seer_reg:4 0.208 0.278 0.445 0.155 0.311 es.mean 
AA/B+ NHW- stage:0 0 0 0 NA NA es.mean 
AA/B+ NHW- stage:99 0.048 0.077 0.269 0.106 NA es.mean 
AA/B+ NHW- income_q:1 0.394 0.335 0.475 0.124 0.638 es.mean 
AA/B+ NHW- income_q:4 0.117 0.154 0.358 0.103 0.638 es.mean 
AA/B+ NHW- hs_q:1 0.083 0.13 0.334 0.142 0.531 es.mean 
AA/B- NHW- stage:0 0 0 0 NA NA es.mean 
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Appendix D. Select Sensitivity Analysis including NHW+ patients 
 
Table D1. Frequency distribution for hemoglobinopathies in the SEER-Medicare study cohort 
 
n % n % n % n % n % n %
Sickle Cell Trait 137 0.78 40 0.03 77 1.11 18 0.03 60 0.56 22 0.03
Sickle Cell Disease 89 0.50 85 0.06 42 0.61 43 0.06 47 0.44 42 0.05
Thalassemia 94 0.53 371 0.25 54 0.78 192 0.28 40 0.37 179 0.23
Other Hemoglobinopathies 96 0.54 520 0.36 44 0.64 262 0.38 52 0.48 258 0.34
Total
a
371 2.10 995 0.68 187 2.70 502 0.73 184 1.71 493 0.64
a
Some patients diagnosed with ≥1 hemoglobinopathy variant
Disorder/Variant
Total
(n = 163,532)
Breast cancer
(n = 76,135)
Prostate cancer
(n= 87,397)
AA/B
(n = 17,674)
NHW
(n = 145,858)
AA/B
(n = 6,919)
NHW
(n = 69,216)
AA/B
(n= 10,755)
NHW
(n = 76,642)
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Table D2. Prevalence of CCI Score by study group  
 
CCI Score n % n % n % n %
0 85 22.9% 6,467 37.4% 71,354 49.3% 408 41.0%
1 79 21.3% 4,152 24.0% 36,753 25.4% 259 26.0%
2 71 19.1% 2,709 15.7% 18,422 12.7% 145 14.6%
3 39 10.5% 1,567 9.1% 8,938 6.2% 64 6.4%
4 36 9.7% 1,080 6.2% 4,821 3.3% 60 6.0%
5+ 61 16.4% 1,328 7.7% 4,575 3.2% 59 5.9%
Total 371 17,303 144,863 995
AA/B+ AA/B- NHW- NHW+
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Table D3. Incidence of adverse events requiring hospitalization 
 
 
 
 
